[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 383
1. Algaba F: Renal adenomas: pathological differential diagnosis with malignant tumors. Adv Urol; 2008;:974848

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal adenomas: pathological differential diagnosis with malignant tumors.
  • The renal adenomas can be confused by imaging diagnosis with malignant renal tumors, but there are also real biological dilemmas to determine their behavior.
  • The consensus decisions are the following. (1) The adenoma of clear cells is not accepted, instead it is considered that all the clear-cell tumors are carcinomas, with greater or lesser aggressiveness. (2) Among the papillary neoplasms the WHO 2004 renal cell tumors classification are considered as papillary adenomas tumors with a maximum diameter of 5 mm and may represent a continuum biological process to papillary renal cell carcinoma.
  • The papillary adenomas associated with End-kidney and/or acquired cystic disease may have a different pathogenesis. (3) To consider a tumor as an oncocytoma the size is not important, only the cytological features, microscopic, ultrastructural, and immunohistochemically can help, but some chromosomal observations introduce some questions about its relation with the chromophobe renal cell carcinoma. (4) Finally, the metanephric adenoma, a tumor with some morphological similarity with the nephroblastoma must be considered in the renal adenomas diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endourol. 2007 Aug;21(8):819-23 [17867935.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):489-500 [17414095.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):239-46 [17056094.001]
  • [Cites] Urology. 2006 Oct;68(4):737-40 [17070344.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):218-24 [16424894.001]
  • [Cites] Am J Clin Pathol. 2006 Feb;125(2):217-22 [16393684.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1275-9 [16287444.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jul 1;152(1):23-8 [15193438.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):101-4 [11172302.001]
  • (PMID = 18846240.001).
  • [ISSN] 1687-6369
  • [Journal-full-title] Advances in urology
  • [ISO-abbreviation] Adv Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2563151
  •  go-up   go-down


2. Aparajita R, Gomez D, Verbeke CS, Menon KV: Papillary adenoma of the distal common bile duct associated with a synchronous carcinoma of the peri-ampullary duodenum. JOP; 2008;9(2):212-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenoma of the distal common bile duct associated with a synchronous carcinoma of the peri-ampullary duodenum.
  • CONTEXT: Benign tumours of the biliary tract are an extremely rare group of neoplasms.
  • Coincidence of a biliary adenoma of the distal common bile duct and a synchronous adenocarcinoma of the peri-ampullary duodenum has never been reported in the literature.
  • CASE REPORT: We report a case of a papillary adenoma in the common bile duct in a 75-year-old female, who had synchronous invasive adenocarcinoma of the peri-ampullary duodenum.
  • CONCLUSION: Isolated papillary adenoma of the bile duct is extremely rare, and in this unusual case it coincided with a peri-ampullary duodenal adenocarcinoma.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Common Bile Duct / pathology. Common Bile Duct Neoplasms / pathology. Duodenal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18326932.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


3. Jones TD, Eble JN, Wang M, MacLennan GT, Delahunt B, Brunelli M, Martignoni G, Lopez-Beltran A, Bonsib SM, Ulbright TM, Zhang S, Nigro K, Cheng L: Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res; 2005 Oct 15;11(20):7226-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas.
  • PURPOSE: In patients with papillary renal cell carcinoma, it is not uncommon to find two or more anatomically distinct and histologically similar tumors at radical nephrectomy.
  • Whether these multiple papillary lesions result from intrarenal metastasis or arise independently is unknown.
  • However, similar clonality assays for multifocal papillary renal cell neoplasia have not been done.
  • All patients had multiple separate papillary lesions (ranging from 2 to 5).
  • Eighteen patients had multiple papillary renal cell carcinomas.
  • Seven had one or more papillary renal cell carcinomas with coexisting papillary adenomas.
  • X-chromosome inactivation analyses were done on the papillary kidney tumors from three female patients.
  • RESULTS: Twenty of 21 (95%) cases showed allelic loss in one or more of the papillary lesions in at least one of the six polymorphic markers analyzed.
  • A concordant pattern of nonrandom X-chromosome inactivation in the coexisting multiple papillary lesions was seen in two of three female patients.
  • CONCLUSION: Our data suggest that, unlike multifocal clear cell renal cell carcinomas, the multiple tumors in patients with papillary renal cell carcinoma arise independently.
  • Thus, intrarenal metastasis does not seem to play an important role in the spread of papillary renal cell carcinoma, a finding that has surgical, therapeutic, and prognostic implications.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Loss of Heterozygosity

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2005 Oct 15;11(20):7206-8 [16243789.001]
  • (PMID = 16243792.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Milas M, Mensah A, Alghoul M, Berber E, Stephen A, Siperstein A, Weber CJ: The impact of office neck ultrasonography on reducing unnecessary thyroid surgery in patients undergoing parathyroidectomy. Thyroid; 2005 Sep;15(9):1055-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colloid nodules/goiters accounted for nearly half of thyroid pathology, followed by follicular adenomas, papillary cancer, thyroiditis, and intrathyroidal parathyroids.
  • Thyroid pathology was similar among single adenomas, multigland, and renal HPT.

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16187914.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


5. Yamaguchi H, Inoue T, Eguchi T, Miyasaka Y, Ohuchida K, Mizumoto K, Yamada T, Yamaguchi K, Tanaka M, Tsuneyoshi M: Fascin overexpression in intraductal papillary mucinous neoplasms (adenomas, borderline neoplasms, and carcinomas) of the pancreas, correlated with increased histological grade. Mod Pathol; 2007 May;20(5):552-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascin overexpression in intraductal papillary mucinous neoplasms (adenomas, borderline neoplasms, and carcinomas) of the pancreas, correlated with increased histological grade.
  • Intraductal papillary mucinous neoplasm (IPMN) is a well-established entity in pancreatic neoplasms and a precursor of infiltrating adenocarcinoma.
  • Fascin expression was significantly higher in borderline neoplasms (25/29, 86%) and carcinomas (37/42, 88%) than in adenomas (23/45, 51%) (P<0.05, respectively), but no difference was observed between borderline neoplasms and carcinomas.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Aged. Female. Humans. Immunohistochemistry. Lasers. Male. Microdissection. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17396145.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 0 / RNA, Messenger; 146808-54-0 / fascin
  •  go-up   go-down


6. Krzeslak A, Gaj Z, Pomorski L, Lipinska A: Expression of cytokeratin 19 in the cytosolic fraction of thyroid lesions: ELISA and Western blot analysis. Mol Med Rep; 2008 Jul-Aug;1(4):565-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results of several studies suggest that CK19 may be useful in the diagnosis of papillary carcinoma, where it has been shown to have strong diffuse cytoplasmic reactivity.
  • The aim of this study was to evaluate, by Western blot analysis and the enzyme-linked immunosorbent assay (ELISA), the expression of CK19 in the cytosolic fraction obtained from 125 specimens of various thyroid lesions: nodular goiters, follicular adenomas, papillary carcinomas, follicular carcinomas and anaplastic carcinomas.
  • The analysis of CK19 expression using the ELISA showed that the majority of papillary carcinoma cases had a much higher level of CK19 than did nodular goiters and adenomas (P<0.001).
  • Western blot analysis revealed the presence of CK19 in 66% of papillary carcinoma cases.
  • CK19 expression was also found in 11, 22, 25 and 25% of nodular goiters, follicular adenomas, and follicular and anaplastic carcinomas, respectively.
  • The results demonstrate that the evaluation of CK19 expression may be helpful in distinguishing papillary carcinoma from other benign and malignant thyroid nodules, but cannot by itself be used to establish a diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21479451.001).
  • [ISSN] 1791-2997
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


7. Kuroki T, Tajima Y, Tsutsumi R, Tsuneoka N, Kitasato A, Adachi T, Kanematsu T: Endoscopic naso-pancreatic stent-guided single-branch resection of the pancreas for multiple intraductal papillary mucinous adenomas. World J Gastroenterol; 2006 Nov 28;12(44):7203-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic naso-pancreatic stent-guided single-branch resection of the pancreas for multiple intraductal papillary mucinous adenomas.
  • In benign or low-grade malignant pancreatic tumors, complete removal of the lesion is sufficient for a cure, and thus minimal resection techniques with preservation of the pancreatic functional reserve have advantages over more extended pancreatic resections.
  • Moreover, branch-type intraductal papillary mucinous neoplasms of the pancreas tend to locate in the head of the pancreas, and show less malignant potential.
  • We describe an endoscopic naso-pancreatic stent-guided single-branch resection of the pancreas for branch-type multiple intraductal papillary mucinous adenomas, along with a gastric wall-covering method for the prevention of pancreatic leakage.
  • [MeSH-major] Adenoma / surgery. Endoscopy, Digestive System / methods. Pancreas / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2000 Jun;179(6):482-4 [11004335.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):156-62 [14505149.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):220-4 [15036200.001]
  • [Cites] Am J Surg. 2006 Jun;191(6):823-6 [16720158.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(1):71-5 [15754104.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(4):283-5 [16133693.001]
  • [Cites] Pancreas. 2004 Apr;28(3):282-8 [15084972.001]
  • (PMID = 17131488.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087787
  •  go-up   go-down


8. Gesierich W, Diwersy C, Leinsinger G, Massmann J, Präuer H, Höfler H, Fend F, Emslander HP: [Papillary adenoma of type-II pneumocytes as a rare differential diagnosis of a solitary pulmonary nodule]. Pneumologie; 2007 Nov;61(11):697-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papillary adenoma of type-II pneumocytes as a rare differential diagnosis of a solitary pulmonary nodule].
  • [Transliterated title] Papilläres Adenom der Typ-II-Pneumozyten als seltene Differenzialdiagnose eines pulmonalen Rundherdes.
  • The case of a 66-year-old, asymptomatic patient with a papillary adenoma of type-II pneumocytes is reported.
  • Papillary adenoma of type-II pneumocytes is a rare tumor, whose origin is suspected in progenitor cells of the bronchioloalveolar epithelium with the potential to differentiate towards type-II pneumocytes and clara cells.
  • The tumor is regarded as benign, however, a malignant potential is not excluded by some authors.
  • [MeSH-major] Adenoma / diagnosis. Lung / pathology. Lung Neoplasms / diagnosis. Solitary Pulmonary Nodule / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17886196.001).
  • [ISSN] 1438-8790
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Papla B: Papillary adenoma of the lung. Pol J Pathol; 2009;60(1):49-51
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenoma of the lung.
  • The report presents a very rare case of papillary adenoma of the lung in a 61-year old man, described for the first time in the Polish literature.
  • [MeSH-major] Adenoma / diagnosis. Lung Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670704.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Pulmonary Surfactant-Associated Protein A; 68238-35-7 / Keratins
  •  go-up   go-down


10. Wang KL, Weinrach DM, Luan C, Han M, Lin F, Teh BT, Yang XJ: Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma. Hum Pathol; 2007 Feb;38(2):239-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma.
  • The purpose of this study is to determine the incidence, histomorphological features, and immunohistochemical features of papillary adenoma and elucidate its potential relationship to RCC.
  • Thirty-eight (7%) nephrectomy specimens showed histologic evidence of papillary adenoma.
  • Of these 38 cases, 18 (47%) arose in the setting of papillary RCC (PRCC).
  • Seven papillary adenomas (18%) occurred in the setting of acquired polycystic kidney disease (APKD), 6 in clear-cell RCCs, 3 in chromophobe RCCs, 2 in end-stage kidney disease, 1 in oncocytoma, 1 in angiomyolipoma, and 1 in renal schwannoma.
  • Furthermore, papillary adenomas were more commonly found in kidneys removed for PRCC (25%, 18/71) than in kidneys harboring clear-cell RCC (1.9%, 6/318).
  • Histomorphologically, papillary adenomas were characterized by varying proportions of papillae and tubules formed by cuboidal cells with scant basophilic cytoplasm similar to those in type 1 PRCC.
  • Adenomas associated with PRCC tend to be multiple in number (61% [11/18] of cases had >2 adenomas; mean, 5).
  • In contrast, 100% of papillary adenomas arising in other conditions had less than 2 adenomas.
  • Most of the adenomas (82%, 31/38) stained strongly for AMACR in a fashion similar to that of PRCC.
  • In this study of surgical specimens, the high coincidence, multifocality, and histologic and immunohistochemical similarities between papillary adenoma and PRCC suggest that the 2 are strongly associated and may represent a continuum of 1 biologic process.
  • In contrast, adenomas associated with APKD exhibit distinct morphological and immunohistochemical features and, therefore, may have an entirely different pathogenesis.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / enzymology. Adenocarcinoma, Clear Cell / pathology. Adenoma. Adenoma, Oxyphilic / enzymology. Adenoma, Oxyphilic / pathology. Adult. Aged. Aged, 80 and over. Angiomyolipoma / enzymology. Angiomyolipoma / pathology. Disease Progression. Female. Glutathione Transferase / analysis. Humans. Immunohistochemistry. Isoenzymes / analysis. Kidney / enzymology. Kidney / pathology. Kidney Failure, Chronic / enzymology. Kidney Failure, Chronic / pathology. Male. Middle Aged. Models, Biological. Polycystic Kidney Diseases / enzymology. Polycystic Kidney Diseases / pathology. Racemases and Epimerases / analysis

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056094.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase alpha; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


11. Katsinelos P, Paroutoglou G, Kountouras J, Beltsis A, Papaziogas B, Mimidis K, Zavos C, Dimiropoulos S: Safety and long-term follow-up of endoscopic snare excision of ampullary adenomas. Surg Endosc; 2006 Apr;20(4):608-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and long-term follow-up of endoscopic snare excision of ampullary adenomas.
  • BACKGROUND: Adenomas of the duodenal papilla are rare.
  • The aim of this retrospective study was to evaluate the safety and outcome of endoscopic snare resection of papillary adenomas in a Greek cohort of patients.
  • METHODS: Fourteen patients (six women and eight men; age range, 42-76 years) were referred for endoscopic management of ampullary adenomas.
  • If there was no common bile and main pancreatic duct invasion and the appearance suggested a benign lesion, biductal sphincterotomy onto normal duodenal tissue was performed.
  • The adenomas were resected via a diathermy snare, along with the major papilla, after elevation of the lesion by epinephrine plus dextrose 50% (1:10,000) solution.
  • RESULTS: Histopathologically, resected tissue included 11 adenomas and three adenomas with focal malignancy, referred for pancreaticoduodenectomy.
  • CONCLUSION: Endoscopic snare resection of adenomas of the major duodenal papilla is a safe, well-tolerated alternative to surgical therapy.
  • [MeSH-major] Adenoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Endoscopy, Digestive System / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16508819.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Morris-Stiff GJ, Senda Y, Verbeke CS, Lodge PA: Papillary adenoma arising in the left hepatic duct: an unusual tumour in an uncommon location. Eur J Gastroenterol Hepatol; 2010 Jul;22(7):886-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for papillary adenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenoma arising in the left hepatic duct: an unusual tumour in an uncommon location.
  • Bile duct adenomas are rare tumours that arise more frequently in the distal extrahepatic biliary tree.
  • We report the case of a papillary adenoma arising at the junction of the common and left hepatic ducts and review the available literature on this rare entity.
  • At laparotomy, there was no evidence of extraductal tumour, and choledochoscopy showed a papillary lesion within the common hepatic and proximal left hepatic ducts.
  • Histological evaluation of the resected specimen confirmed a papillary adenoma with mild dysplasia.
  • [MeSH-major] Adenoma / diagnosis. Adenoma, Bile Duct / diagnosis. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20545030.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.3.2.2 / gamma-Glutamyltransferase
  • [Number-of-references] 10
  •  go-up   go-down


13. Nelson KK, Gattuso P, Xu X, Prinz RA: Expression of the sonic hedgehog pathway molecules in synchronous follicular adenoma and papillary carcinoma of the thyroid gland in predicting malignancy. Surgery; 2010 Oct;148(4):654-60; discussion 660
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the sonic hedgehog pathway molecules in synchronous follicular adenoma and papillary carcinoma of the thyroid gland in predicting malignancy.
  • This study determines whether 3 molecules, Patched, Smoothened, and Sonic Hedgehog, involved in the Sonic Hedgehog pathway are overexpressed equally in synchronous follicular thyroid adenoma and papillary thyroid carcinoma.
  • METHODS: Eighteen patients with synchronous follicular thyroid adenoma and papillary thyroid carcinoma underwent thyroidectomy.
  • Patched expression was detected in 5 of 13 (38%) follicular adenomas and 5 of 12 (42%) papillary carcinomas.
  • Smoothened was expressed in 4 of 13 (31%) follicular adenomas and 3 of 13 (23%) papillary carcinomas.
  • Sonic Hedgehog was expressed in 4 of 13 (31%) follicular adenomas and 11 of 13 (85%) papillary carcinomas.
  • CONCLUSION: Expression of the 3 molecules involved in the Sonic Hedgehog pathway was similar in follicular thyroid adenoma, but Sonic Hedgehog expression was a more sensitive indicator of malignancy in papillary thyroid carcinoma.
  • The Sonic Hedgehog molecule may become a diagnostic marker when the cytologic or histologic features are not characteristic of a papillary carcinoma.
  • Greater understanding of the Sonic Hedgehog pathway may provide molecular methods for preventing or treating papillary thyroid carcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Adenoma / metabolism. Hedgehog Proteins / biosynthesis. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20797751.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / SHH protein, human
  •  go-up   go-down


14. Sotona O, Cecka F, Neoral C, Ferko A, Rejchrt S, Podhola M, Subrt Z, Jon B: Papillary adenoma of the extrahepatic biliary tract--a rare cause of obstructive jaundice. Acta Gastroenterol Belg; 2010 Apr-Jun;73(2):270-3
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenoma of the extrahepatic biliary tract--a rare cause of obstructive jaundice.
  • The authors present a case of papillary adenoma of the extrahepatic biliary tract presenting as obstructive jaundice.
  • Adenoma of the bile duct is a rare entity.
  • [MeSH-major] Adenoma / complications. Bile Duct Neoplasms / complications. Bile Ducts, Extrahepatic. Jaundice, Obstructive / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20690568.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


15. Bhattacharya TK, Rani S, Maiti SK, Dayal S, Kumar P, Sharma A: Polymorphism of ZuBeCa3 microsatellite and its association with mammary tumor in dogs. Int J Immunogenet; 2007 Jun;34(3):161-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological observation classified the cancer-affected animals into three groups namely, malignant solid mammary carcinoma, malignant papillary adenocarcinoma and benign papillary adenoma in which the frequency of A allele was relatively more predominant in benign tumor group, which is more than 80%.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Adenoma / genetics. Breast Neoplasms / genetics. Carcinoma / genetics. Microsatellite Repeats / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504505.001).
  • [ISSN] 1744-3121
  • [Journal-full-title] International journal of immunogenetics
  • [ISO-abbreviation] Int. J. Immunogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Baek SK, Woo JS, Kwon SY, Lee SH, Chae YS, Jung KY: Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma. Laryngoscope; 2007 May;117(5):911-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma.
  • OBJECTIVES: The aim of the present study was to examine the expressions of mucin genes MUC1 and MUC4 and to evaluate the difference of their expressions in normal thyroid tissue, follicular adenoma, and papillary carcinoma.
  • Furthermore, we aimed to estimate their prognostic significance in papillary carcinoma.
  • METHODS: We performed semiquantitative reverse-transcription polymerase chain reaction for determining the MUC1 and MUC4 mRNA expressions, and immunohistochemical staining was performed to determine the MUC1 and MUC4 protein expressions in 22 normal thyroid tissues, 22 follicular adenomas, and 15 papillary carcinomas.
  • The semiquantitative scoring of the immunohistochemical staining was compared with the prognostic factors for thyroid carcinoma to evaluate the prognostic significance in 87 papillary carcinoma patients.
  • RESULTS: The MUC1 mRNA of the papillary carcinoma tissue showed an increased expression level compared with the other tissues.
  • MUC1 immunoreactivity was more intense in papillary carcinoma but not in the other tissues.
  • CONCLUSIONS: Up-regulation of MUC1 may play a more important role than that of MUC4 in the development of thyroid papillary carcinoma, and it may have some significance as a prognostic factor.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Mucin-1 / metabolism. Mucins / metabolism. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473695.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-1; 0 / Mucin-4; 0 / Mucins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


17. Kuwahara M, Nagafuchi M, Rikimaru T, Iwasaki A, Shirakusa T: Pulmonary papillary adenoma. Gen Thorac Cardiovasc Surg; 2010 Oct;58(10):542-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary papillary adenoma.
  • We present a rare case of solitary pulmonary papillary adenoma.
  • The previous physician had considered it to be an old benign inflammatory granuloma and had kept it under observation.
  • On postoperative pathology examination, the nodule was found to be a circumscribed nodule consisting of a papillary growth of cuboidal to low-columnar epithelial cells lining the surface of a fibrovascular stroma.
  • The histological features were consistent with pulmonary papillary adenoma.
  • Only 20 cases of pulmonary papillary adenoma have been reported in the literature.
  • [MeSH-major] Adenoma / pathology. Lung Neoplasms / pathology. Solitary Pulmonary Nodule / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20941571.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Clerici T, Kolb W, Beutner U, Bareck E, Dotzenrath C, Kull C, Niederle B, German Association of Endocrine Surgeons: Diagnosis and treatment of small follicular thyroid carcinomas. Br J Surg; 2010 Jun;97(6):839-44
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most initial diagnoses had to be revised because of incorrect size assessment or incorrect diagnosis (benign adenoma, papillary thyroid carcinoma (PTC), follicular variant of PTC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473996.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Investigator] Kaserer K; Perren A; Schmid KW; Köberle-Wührer R; Wenzl E; Asari R; Klinge U; Müller G; Kroell KP; Blankenburg C; Voss H; Cupisti K; Witte J; Knoefel WT; Simon D; Lienenlüke RH; Vorländer C; Wacha H; Schabram J; Lorenz K; Dralle H; Wojciechowski B; Kussmann J; Weber Y; Schürmann G; Goretzki PE; Ulitzer H; Eberle A; Mayer M; Stabenow R; Stegmaier C; Bühlmann R; Schlumpf R; Triponez F; Ess SM
  •  go-up   go-down


19. Gokden N, Li L, Zhang H, Schafer RF, Schichman S, Scott MA, Smoller BR, Fan CY: Loss of heterozygosity of DNA repair gene, hOGG1, in renal cell carcinoma but not in renal papillary adenoma. Pathol Int; 2008 Jun;58(6):339-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity of DNA repair gene, hOGG1, in renal cell carcinoma but not in renal papillary adenoma.
  • Even though some studies found similar genetic alterations between renal papillary adenomas (PA) and papillary RCC (PRCC), no studies have been conducted to compare the alterations of hOGG1 gene in PA, PRCC and CC-RCC.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Renal Cell / genetics. DNA Glycosylases / genetics. DNA Repair / genetics. Kidney Neoplasms / genetics


20. Oikonomou E, Barreto DC, Soares B, De Marco L, Buchfelder M, Adams EF: Beta-catenin mutations in craniopharyngiomas and pituitary adenomas. J Neurooncol; 2005 Jul;73(3):205-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-catenin mutations in craniopharyngiomas and pituitary adenomas.
  • Craniopharyngiomas and pituitary adenomas are both tumors of the hypothalamic and pituitary region, respectively that are frequently associated with endocrine defects either because of direct involvement of hormone producing cells (most pituitary tumors) or because of secondary defects due to disturbance of hypothalamic function (some pituitary tumors and craniopharyngiomas).
  • Some studies suggest that mutant beta-catenin gene cells in craniopharyngiomas and pituitary adenomas contribute to their tumorigenesis.
  • None of the 22 pituitary adenomas and the eight papillary craniopharyngiomas analyzed presented any sequence alterations.
  • [MeSH-major] Adenoma / genetics. Craniopharyngioma / genetics. Cytoskeletal Proteins / genetics. Pituitary Neoplasms / genetics. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980970.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


21. Schittenhelm J, Psaras T, Meyermann R, Honegger J, Beschorner R: Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms. Folia Neuropathol; 2010;48(2):75-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms.
  • OBJECTIVES: Previous studies have shown an inverse correlation between the expression of CDX2 (also known as CDX3) and tumour grade, stage and lymph node dissemination in colorectal adenomas and adenocarcinomas.
  • Furthermore, only very few data are available on CDX2 expression in normal pituitary gland tissue and/or pituitary adenomas.
  • MATERIAL AND METHODS: We investigated CDX2 expression in 28 normal pituitary glands, 75 pituitary adenomas of varying hormonal activity (including 7 invasive adenomas and 7 atypical adenomas) and 23 craniopharyngiomas (17 adamantinous and 6 papillary) in tissue microarrays.
  • RESULTS: None of the pituitary adenomas, craniopharyngiomas and normal pituitary glands showed expression of CDX2.
  • CONCLUSIONS: There is no evidence for that CDX2 might play a role in tumourigenesis, invasive growth or tumour recurrence of pituitary adenomas or in tumourigenesis of craniopharyngiomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20602288.001).
  • [ISSN] 1509-572X
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


22. Azabdaftari G, Alroy J, Banner BF, Ucci A, Bhan I, Cheville JC: S100 protein expression distinguishes metanephric adenomas from other renal neoplasms. Pathol Res Pract; 2008;204(10):719-23
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100 protein expression distinguishes metanephric adenomas from other renal neoplasms.
  • Metanephric adenoma is a benign renal neoplasm with morphologic features similar to those of malignant renal neoplasms, such as papillary renal cell carcinoma (RCC) and Wilms' tumor.
  • Different methods have been used to distinguish between metanephric adenoma and papillary RCC and Wilms' tumor.
  • In the current study, we compared the expression of S100 protein in 15 cases of metanephric adenoma, 10 cases of Wilms' tumor, and 13 cases of papillary RCC.
  • Our results revealed strong expression of S100 proteins in all cases of metanephric adenoma, weak expression in two cases of Wilms' tumor, and no expression in any of the cases of papillary RCC.
  • These findings indicate that S100 could be a useful and accessible tool for the diagnosis of metanephric adenoma.
  • [MeSH-major] Adenoma / chemistry. Carcinoma, Renal Cell / chemistry. Kidney Neoplasms / chemistry. S100 Proteins / analysis. Wilms Tumor / chemistry

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621486.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / S100 Proteins
  •  go-up   go-down


23. Bryson PC, Shores CG, Hart C, Thorne L, Patel MR, Richey L, Farag A, Zanation AM: Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas. Arch Otolaryngol Head Neck Surg; 2008 Jun;134(6):581-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
  • OBJECTIVES: To use immunohistochemical (IHC) evaluation of proteins encoded by genes that were differentially expressed in follicular thyroid adenomas (FAs) vs follicular thyroid carcinomas (FTCs) to distinguish benign vs malignant follicular thyroid lesions.
  • Multiple gene microarray studies suggest that benign and malignant follicular thyroid neoplasms have different gene expression profiles.
  • DESIGN: Immunohistochemical analysis of thyroid neoplasms, including FA (n = 62), FTC (n = 62), and follicular variant of papillary thyroid carcinoma (n = 58), using tissue microarrays.
  • PATIENTS: Adults with known follicular and papillary thyroid lesions that were surgically resected during the past 15 years.
  • MAIN OUTCOME MEASURES: Sensitivity and specificity of individual and combined antibodies for detecting benign from malignant lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenoma / diagnosis. Thyroid Neoplasms / diagnosis


24. Puppa G, Gervasio A, Yorukoglu K, Colombari R, De Marchi F, Canzonieri V: Huge renal cyst with parietal renal cell carcinoma, osseous metaplasia and a papillary adenoma: a case report with unique clinicopathological features and literature review. Virchows Arch; 2008 Mar;452(3):325-30
MedlinePlus Health Information. consumer health - Kidney Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge renal cyst with parietal renal cell carcinoma, osseous metaplasia and a papillary adenoma: a case report with unique clinicopathological features and literature review.
  • The unique clinicopathological features of a giant solitary renal cyst with a parietal clear cell carcinoma in contiguity with a focus of osseous metaplasia and a papillary adenoma are reported.
  • After extensive pathological sampling of the cyst's wall, a focus of osseous metaplasia in contiguity with the main tumour and a microscopic papillary adenoma were found.
  • [MeSH-major] Adenoma / pathology. Carcinoma, Renal Cell / pathology. Kidney Diseases, Cystic / pathology. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18080136.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Keratin-7; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 19
  •  go-up   go-down


25. Goldfarb M, O'Neal P, Shih JL, Hartzband P, Connolly J, Hasselgren PO: Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidism. Endocr Pract; 2009 Jul-Aug;15(5):463-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidism.
  • OBJECTIVE: To describe a patient presenting with the rare constellation of synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma.
  • He was found to have a 3.4-cm parathyroid carcinoma on the left side and a 3.2-cm papillary carcinoma in the right thyroid lobe.
  • In addition, a 917-mg parathyroid adenoma was found on the right side.
  • To our knowledge, our patient is the first documented case with a parathyroid adenoma in addition to synchronous parathyroid and thyroid carcinomas.
  • The presence of concurrent parathyroid carcinoma and parathyroid adenoma can cause diagnostic confusion and should be considered in patients presenting with severe hyperparathyroidism.

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ear Nose Throat J. 2002 Jun;81(6):395-8, 400-1 [12092283.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):255-64 [17559137.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):485-93 [11157996.001]
  • [Cites] Surg Oncol. 1999 Nov;8(3):155-65 [11113666.001]
  • [Cites] Mayo Clin Proc. 2002 Aug;77(8):866-9 [12173721.001]
  • [Cites] Am J Otolaryngol. 2002 Nov-Dec;23(6):382-5 [12430133.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):54-64 [12605367.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1722-9 [14585940.001]
  • [Cites] Cancer. 1973 Mar;31(3):600-5 [4693587.001]
  • [Cites] Nihon Gan Chiryo Gakkai Shi. 1979 Dec 20;14(7):1127-35 [541539.001]
  • [Cites] Br J Surg. 1988 Sep;75(9):873-4 [3179662.001]
  • [Cites] J Chin Med Assoc. 2005 Feb;68(2):87-91 [15759821.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1345-53 [16237743.001]
  • [Cites] Br J Surg. 2007 May;94(5):566-70 [17380564.001]
  • [Cites] J Endocrinol Invest. 2001 Jan;24(1):42-4 [11227731.001]
  • (PMID = 19491068.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] ENG
  • [Grant] United States / NINR NIH HHS / NR / NR008545-06; United States / NINR NIH HHS / NR / R56 NR008545; United States / NINR NIH HHS / NR / R56 NR008545-06
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS217054; NLM/ PMC2917245
  •  go-up   go-down


26. Schönleben F, Qiu W, Allendorf JD, Chabot JA, Remotti HE, Su GH: Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg; 2009 Aug;13(8):1510-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
  • BACKGROUND: Mutations of KRAS are known to occur in periampullary and ampullary adenomas and carcinomas.
  • While oncogenic BRAF contributes to the tumorigenesis of both pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasms/carcinomas (IPMN/IPMC), PIK3CA mutations were only detected in IPMN/IPMC.
  • This study aimed to elucidate possible roles of BRAF and PIK3CA in the development of ampullary and periampullary adenomas and carcinomas.
  • METHODS: Mutations of BRAF, NRAS, HRAS, KRAS, and PIK3CA were evaluated in seven adenomas, seven adenomas with carcinoma in situ, and 21 adenocarcinomas of the periampullary duodenal region and the ampulla of Vater.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2756-60 [7796400.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1875-8 [7753564.001]
  • [Cites] J Clin Pathol. 1996 Jun;49(6):460-4 [8763258.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1731-4 [9135016.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] FEBS Lett. 1997 Jun 23;410(1):91-5 [9247130.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):129-33 [9815548.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]
  • [Cites] Cancer Biol Ther. 2004 Aug;3(8):772-5 [15254419.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1477-80 [15608678.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1441-6 [16533766.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):163-70 [16478646.001]
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):34-46 [10579909.001]
  • [Cites] World J Surg. 2000 Jan;24(1):54-9 [10594204.001]
  • [Cites] Biochem J. 2000 Mar 15;346 Pt 3:561-76 [10698680.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1821-5 [10854204.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):543-55 [11459270.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:615-75 [11687500.001]
  • [Cites] Biol Cell. 2001 Sep;93(1-2):53-62 [11730323.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7420-5 [12032298.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7001-3 [12460919.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):1983-93 [12612072.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):272-8 [12640108.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1684-95 [12670923.001]
  • [Cites] Cancer Lett. 2003 Sep 25;199(2):169-73 [12969789.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1255-60 [14507635.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5048-50 [15289301.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] Hum Pathol. 1985 Mar;16(3):305-10 [3972407.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • (PMID = 19440799.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109525-05; United States / NCI NIH HHS / CA / R21 CA127701; United States / NCI NIH HHS / CA / CA127701-01A2; United States / NCI NIH HHS / CA / R01CA109525; United States / NCI NIH HHS / CA / R01 CA109525; United States / NCI NIH HHS / CA / CA109525-05; United States / NCI NIH HHS / CA / R21 CA127701-01A2; United States / NCI NIH HHS / CA / R21CA127701
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS164917; NLM/ PMC3915027
  •  go-up   go-down


27. Nucera C, Mazzon E, Caillou B, Violi MA, Moleti M, Priolo C, Sturniolo G, Puzzolo D, Cavallari V, Trimarchi F, Vermiglio F: Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia. J Endocrinol Invest; 2005 Feb;28(2):106-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia.
  • Increasing hgal-3 immunoexpression has been reported in several human tumors, including thyroid carcinomas, but not in benign thyroid lesions.
  • We analyzed the immunolocalization of hgal-3 in cell compartments of benign and malignant thyroid lesions.
  • Hgal-3 immunoperoxidase reaction was carried out on 133 thyroid tissue samples obtained from 113 patients; 20 of these were normal (NT), 85 were benign thyroid lesions [20 colloid nodules (CN), 21 nodular hyperplasias (NH), 7 focal lymphocytic thyroiditis (FLT), 15 Hashimoto's thyroiditis (HT), 22 follicular adenomas (FA)], 25 differentiated carcinomas [15 papillary carcinomas (PC), 6 follicular carcinomas (FC) and 4 Hürthle cell carcinomas (HC)] and 3 anaplastic carcinomas (AC).
  • Conversely, hgal-3 immunoexpression was absent in NT and in all benign thyroid lesions, but 1/15 HT and 10/22 (45.4%) FA.
  • Moreover, hgal-3 expression in FA might anticipate the likelihood of evolution of these benign lesions towards malignancy.
  • [MeSH-major] Adenoma / chemistry. Adenoma / pathology. Galectin 3 / analysis. Thyroid Neoplasms / chemistry. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15887854.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down


28. Fan F, Lai EC, Xie F, Yang JM, Xu F, Kan T, Shen RX, Yang XY, Lau Wan Y, Wu MC: Intraductal papillary mucinous neoplasms of the pancreas--predictors of malignancy. Hepatogastroenterology; 2010 May-Jun;57(99-100):635-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas--predictors of malignancy.
  • BACKGROUND/AIMS: Preoperative determination of malignancy in Intraductal Papillary Mucinous Neoplasms (IPMN) remains problematic.
  • RESULTS: Thirteen patients (32.5%) had adenomas, 4 (10%) borderline IPMN, 18 (45%) carcinoma in situ, and 5 (12.5%) invasive carcinoma.
  • Patients with benign IPMN had 1-, 3-, and 5-year overall survival rates of 100%, 94.1%, and 88.2%, respectively and 1-, 3-, and 5-year disease-free survival rates of 100%, 94.1%, and 88.2%, respectively.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698241.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


29. Szponar A, Yusenko MV, Kovacs G: High-resolution array CGH of metanephric adenomas: lack of DNA copy number changes. Histopathology; 2010 Jan;56(2):212-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution array CGH of metanephric adenomas: lack of DNA copy number changes.
  • AIMS: Previous karyotyping and fluorescence in situ hybridization analysis of metanephric adenomas (MAs) has yielded controversial data.
  • METHODS AND RESULTS: DNA extracted from paraffin blocks of six metanephric adenomas was hybridized onto Agilent oligoarrays with approximately 43,000 in situ synthesized 60-mer oligonucleotide probes that span coding and non-coding sequences with an average spatial resolution of approximately 35 kb.
  • None of the metanephric adenomas showed DNA copy number changes.
  • CONCLUSIONS: Our high-resolution oligoarray analysis indicates that metanephric adenomas lack DNA copy number alterations.
  • This finding may help to differentiate between metanephric adenomas from Wilms' tumour and papillary renal cell adenoma with overlapping phenotype.
  • [MeSH-major] Adenoma / genetics. DNA Copy Number Variations. Kidney Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102400.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Munshi AG, Hassan MA: Common bile duct adenoma: case report and brief review of literature. Surg Laparosc Endosc Percutan Tech; 2010 Dec;20(6):e193-4
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for bile duct adenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common bile duct adenoma: case report and brief review of literature.
  • Papillary adenomas of the common bile duct are a rare entity with few published case reports and limited knowledge on its natural progression.
  • We report here a case of common bile duct papillary adenoma in a 69-year-old female who presented with symptoms of common bile duct obstruction.
  • She was treated with local endoscopic excision of the mass that has benign features.
  • A brief review of literature is discussed with a proposed treatment plan for follow-up with surveillance endoscopy and ultrasonography as opposed to the radical resection for benign findings on pathology.
  • [MeSH-major] Adenoma / surgery. Common Bile Duct Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150400.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


31. van Staveren WC, Solís DW, Delys L, Venet D, Cappello M, Andry G, Dumont JE, Libert F, Detours V, Maenhaut C: Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc Natl Acad Sci U S A; 2006 Jan 10;103(2):413-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis.
  • Thyroid-stimulating hormone (TSH) receptor and Gsalpha activating mutations have been detected in thyroid autonomous adenomas, Gsalpha mutations in growth hormone-secreting pituitary adenomas, and PKAR1A mutations in Carney complex, a multiple neoplasia syndrome.
  • The gene expression profile of the long-term stimulated cultures resembled the autonomous adenomas, but not papillary carcinomas.
  • The molecular phenotype of the adenomas thus confirms the role of long-term stimulation of the TSH-cAMP cascade in the pathology.
  • Some were down- or nonregulated in adenomas, suggesting a loss of negative feedback control in the tumors.
  • [MeSH-major] Adenoma / genetics. Adenoma / pathology. Cell Transformation, Neoplastic / genetics. Gene Expression Regulation, Neoplastic. Thyroid Gland / cytology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Endocrinol. 2003 May 30;203(1-2):129-35 [12782409.001]
  • [Cites] Thyroid. 2003 Feb;13(2):149-58 [12699589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):69-90 [12946479.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):795-804 [14737114.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 11;1697(1-2):71-9 [15023351.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] Mol Hum Reprod. 2004 May;10(5):299-311 [15026540.001]
  • [Cites] J Endocrinol. 2004 Jul;182(1):173-82 [15225142.001]
  • [Cites] J Mol Endocrinol. 2004 Aug;33(1):51-8 [15291742.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] Endocrinology. 2004 Sep;145(9):4251-63 [15192045.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3531-9 [15337802.001]
  • [Cites] Eur J Endocrinol. 2004 Sep;151(3):383-90 [15362969.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Dan Med Bull. 1987 Apr;34(2):121-3 [3556045.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Jun;66(6):1158-65 [2836470.001]
  • [Cites] Oncogene. 1990 Jul;5(7):1059-61 [2115641.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):663-72 [2199463.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1725-33 [1333055.001]
  • [Cites] Nature. 1993 Oct 14;365(6447):649-51 [8413627.001]
  • [Cites] Endocrinology. 1994 Sep;135(3):1212-9 [8070365.001]
  • [Cites] Endocrinology. 1996 Nov;137(11):4691-8 [8895335.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2695-701 [9253356.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6717-26 [9343436.001]
  • [Cites] Eur J Endocrinol. 1997 Dec;137(6):579-98 [9437219.001]
  • [Cites] Eur J Biochem. 1999 Jan;259(1-2):370-8 [9914516.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):829-34 [10084556.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 [10430922.001]
  • [Cites] J Cell Physiol. 1999 Nov;181(2):342-54 [10497313.001]
  • [Cites] Head Neck. 2004 Dec;26(12):1069-83 [15515157.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6902-16 [16027733.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Thyroid. 2000 Feb;10(2):131-40 [10718549.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Apr;278(4):E611-9 [10751193.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2872-8 [10946896.001]
  • [Cites] Mol Cell Endocrinol. 2000 Dec 22;170(1-2):185-96 [11162902.001]
  • [Cites] Nature. 2001 Feb 22;409(6823):1051-5 [11234015.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Endocrinology. 2001 Jul;142(7):2961-7 [11416017.001]
  • [Cites] Biochim Biophys Acta. 2001 Jul 25;1540(1):68-81 [11476896.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):e15 [11842121.001]
  • [Cites] Int J Biochem Cell Biol. 2002 May;34(5):432-8 [11906816.001]
  • [Cites] J Endocrinol. 2002 May;173(2):345-55 [12010642.001]
  • [Cites] Biotechniques. 2002 Jun;32(6):1330-4, 1336, 1338, 1340 [12074164.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;968:106-21 [12119271.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):710-8 [12209131.001]
  • [Cites] Exp Cell Res. 2002 Sep 10;279(1):62-70 [12213214.001]
  • [Cites] J Pathol. 2002 Oct;198(2):157-62 [12237874.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5493-6 [12493749.001]
  • [Cites] Bioinformatics. 2003 Mar 22;19(5):659-60 [12651728.001]
  • [Cites] FEBS Lett. 2003 Jul 3;546(1):59-64 [12829237.001]
  • (PMID = 16381821.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 9002-71-5 / Thyrotropin
  • [Other-IDs] NLM/ PMC1326163
  •  go-up   go-down


32. Albores-Saavedra J, Wu J: The many faces and mimics of papillary thyroid carcinoma. Endocr Pathol; 2006;17(1):1-18
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The many faces and mimics of papillary thyroid carcinoma.
  • This article provides an overview of the 15 histologic variants of papillary thyroid carcinoma listed by the 2004 World Health Organization (WHO) monograph on endocrine tumors.
  • The follicular variants (conventional and macrofollicular) constitute a morphologic challenge because the majority of these tumors are encapsulated and, also, because, in many tumors, not all neoplastic cells show the nuclear features considered to be diagnostic of papillary carcinoma.
  • Moreover, hyperplastic thyroid lesions, follicular adenomas, and Hashimoto's thyroiditis may contain cells with clear nuclei resembling those of papillary carcinoma.
  • Papillary carcinomas composed entirely of hyperchromatic cells have been overlooked.
  • The WHO monograph defines papillary carcinoma with focal spindle and giant cell carcinoma components but its clinical behavior is unknown.
  • Papillary carcinoma with an insular pattern that does not show the artifactual separation of the cell nests has been misinterpreted as the solid variant of papillary carcinoma.
  • Papillary microcarcinomas include not only the conventional type and the follicular variants but also the tall cell and columnar cell variants.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenoma / diagnosis. Cell Nucleus / pathology. Diagnosis, Differential. Hashimoto Disease / diagnosis. Humans. Hyperplasia / diagnosis. Thyroid Gland / pathology. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760576.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


33. Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M, Vax V, Garcia E, Czirják S, Hanzély Z, Kola B, Korbonits M, Grossman AB: A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf); 2007 Mar;66(3):348-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mutation and expression analysis of the oncogene BRAF in pituitary adenomas.
  • OBJECTIVE: BRAF is an oncogene that is commonly mutated in both melanomas and papillary thyroid carcinomas, usually at position V600E that leads to constitutive activity in the Ras-mitogen-activated protein kinase (MAPK) pathway.
  • We speculated that this same gene may be either mutated at this site, or overexpressed, in pituitary adenomas.
  • DESIGN AND MEASUREMENTS: We sequenced 37 pituitary adenomas for a mutation at the V600E position.
  • In addition, we investigated B-Raf mRNA expression in normal pituitary (n = 5) and nonfunctioning pituitary adenomas (NFPA) (n = 6) by semiquantitative PCR, and in a further 27 pituitary adenomas of various types and 10 normal pituitaries using real-time quantitative PCR.
  • B-Raf mRNA was overexpressed in pituitary adenomas compared to normal pituitary, and this was entirely due to overexpression in NFPAs.
  • CONCLUSIONS: Mutations previously seen in the majority of melanomas and a substantial minority of papillary thyroid carcinomas are not a frequent finding in pituitary adenomas.
  • [MeSH-major] Adenoma / chemistry. DNA Mutational Analysis. Gene Expression Regulation, Neoplastic. Pituitary Neoplasms / chemistry. Proto-Oncogene Proteins B-raf / genetics. RNA, Messenger / analysis
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / chemistry. Case-Control Studies. Growth Hormone-Secreting Pituitary Adenoma / chemistry. Humans. Polymerase Chain Reaction / methods. Prolactinoma / chemistry. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302867.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


34. Matusan K, Dordevic G, Mozetic V, Lucin K: Expression of osteopontin and CD44 molecule in papillary renal cell tumors. Pathol Oncol Res; 2005;11(2):108-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of osteopontin and CD44 molecule in papillary renal cell tumors.
  • The aim of the study was to analyze the expression of CD44 adhesion molecule and its ligand osteopontin in papillary renal cell tumors, and to assess the possible prognostic significance of CD44 and osteopontin expression in papillary renal cell carcinomas.
  • The expression of the standard and v6 exon containing isoforms of CD44 molecule, as well as of its ligand osteopontin, was immunohistochemically evaluated in 43 papillary renal cell tumors, which included 5 adenomas and 38 carcinomas.
  • In order to assess their prognostic significance, the results obtained in papillary renal cell carcinomas were compared to usual clinicopathological parameters such as tumor size, histological grade, pathological stage, and Ki-67 proliferation index.
  • Papillary renal cell adenomas were generally negative for CD44s, except for focal positivity found in one sample.
  • The osteopontin protein was detected in all adenomas and all papillary renal cell carcinomas, except one.
  • Our results show constitutive expression of osteopontin in papillary renal tumors, including papillary renal cell adenomas.
  • The upregulation of CD44s and v6 isoforms, although found in a considerable number of papillary renal cell carcinomas, does not appear to have any prognostic value in this type of renal cancer.
  • [MeSH-major] Antigens, CD44 / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Sialoglycoproteins / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Female. Humans. Kidney / metabolism. Kidney / pathology. Male. Neoplasm Staging. Osteopontin

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999156.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


35. Nygaard B, Frisch T, Kiss K: [Thyroid papillary cancer using TPO staining]. Ugeskr Laeger; 2008 Apr 28;170(18):1571
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thyroid papillary cancer using TPO staining].
  • Immunostaining for TPO (MoAb47) has been used to predict the risk of thyroid cancer in thyroid adenomas without uptake in thyroid 99m pertechnetate scintigraphy.
  • This case describes a 16-year-old girl with thyroid papillary cancer staining 95% positive using TPO staining.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Papillary / diagnosis. Iodide Peroxidase / analysis. Staining and Labeling / methods. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454932.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


36. Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, Rumilla K, Lloyd RV: Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol; 2006;17(3):213-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.
  • These analyses showed that several antibodies were useful in distinguishing follicular adenomas from follicular variant of papillary thyroid carcinomas including HBME-1, CITED1, galectin-3, cytokeratin 19, and S100A4 (p < 0.0001).
  • A combination of markers consisting of a panel of HBME-1, galectin-3, and CK19 or a panel of HBME-1, CITED1, and galectin-3 was usually most effective in distinguishing follicular adenoma from follicular variant of papillary thyroid carcinoma.
  • These results indicate that some individual antibodies or a panel of antibodies combined with histopathological analysis can be useful in separating follicular adenoma (FA) from follicular variant of papillary thyroid carcinoma (FVPTC).
  • [MeSH-major] Adenoma / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Papillary, Follicular / diagnosis. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17308358.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Kataoka TR, Ioka T, Tsukamoto Y, Matsumura M, Ishiguro S, Nishizawa Y: Nuclear expression of STAT5 in intraductal papillary mucinous neoplasms of the pancreas. Int J Surg Pathol; 2007 Jul;15(3):277-81
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear expression of STAT5 in intraductal papillary mucinous neoplasms of the pancreas.
  • Intraductal papillary mucinous neoplasms (IPMNs) are noninvasive lesions of the pancreas and classified as intraductal papillary mucinous adenomas (IPMAs), borderline IPMNs, and intraductal papillary mucinous carcinomas (IPMCs).
  • [MeSH-major] Adenoma / metabolism. Cell Nucleus / metabolism. Pancreatic Neoplasms / metabolism. STAT5 Transcription Factor / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652536.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT5 Transcription Factor; 0 / STAT5B protein, human
  •  go-up   go-down


38. Tsukahara M, Nagai H, Kamiakito T, Kawata H, Takayashiki N, Saito K, Tanaka A: Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas. Pathol Int; 2005 Feb;55(2):63-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas.
  • The expression of claudin-4 was investigated in human pancreas, pancreatic ductal adenocarcinomas, and intraductal papillary-mucinous tumors of the pancreas (IPMT), and compared with that of claudin-1.
  • In 44 lesions of 22 cases of IPMT, including six hyperplastic foci distant from the main lesions, clauidin-1 was positive in three out of six (50%) hyperplastic foci, 14 out of 17 (82%) adenomas, three out of 10 (30%) borderline tumors, two out of six (33%) non-invasive carcinomas, and one out of five (20%) invasive carcinomas, producing a statistically negative correlation with histological tumor grades.
  • In contrast, claudin-4 was negative in the six hyperplastic foci, and positive in four out of the 17 (24%) adenomas, five out of the 10 (50%) borderline tumors, five out of the six (83%) non-invasive carcinomas, and four out of the five (80%) invasive carcinomas, producing a statistically positive correlation with histological tumor grades.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Papillary / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Membrane Proteins / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Claudin-1. Claudin-4. Female. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged. Pancreas / metabolism. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693851.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


39. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM, Santoro M: Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab; 2005 Sep;90(9):5270-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness.
  • The transmembrane glycoprotein CD44v6 is overexpressed in most papillary thyroid carcinomas (PTC).
  • DESIGN: Thyroid samples from 117 patients who had undergone surgical resection of the thyroid gland for benign or malignant lesions were collected.
  • RESULTS: In this study we show that OPN is overexpressed in human PTCs with respect to normal thyroid tissue, follicular adenomas, and multinodular goiters (P < 0.05).
  • [MeSH-major] Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Sialoglycoproteins / metabolism. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15998773.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


40. Wang SL, Li SH, Chen WT, Chai CY: Expression of D2-40 in adjunct diagnosis of papillary thyroid carcinoma. APMIS; 2007 Aug;115(8):906-10
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of D2-40 in adjunct diagnosis of papillary thyroid carcinoma.
  • The clinical pathologic criteria for nuclear features of papillary thyroid carcinoma are subjective and sometimes cannot distinguish carcinoma from adenomatous goiter and follicular neoplasms.
  • Using quantitative analysis of immunohistochemical staining with D2-40, a recently available monoclonal antibody used as a lymphatic endothelial marker, we examined 72 cases of papillary carcinoma.
  • Controls included 36 follicular adenomas, 36 follicular carcinomas, and 20 adenomatous goiters with papillary hyperplasia.
  • Cytoplasmic D2-40 immunoreactivity was present in 60 of 72 papillary carcinomas, 2 cases of follicular adenoma and 2 cases of follicular carcinoma, whereas no adenomatous goiter or normal thyroid glands contained positive epithelial cells.
  • Overexpression of D2-40 in papillary thyroid carcinomas thus has potential diagnostic utility in differentiating these tumors from their potential histologic mimics.
  • [MeSH-major] Antibodies, Monoclonal. Biomarkers, Tumor / analysis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696946.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


41. Sarquis MS, Weber F, Shen L, Broelsch CE, Jhiang SM, Zedenius J, Frilling A, Eng C: High frequency of loss of heterozygosity in imprinted, compared with nonimprinted, genomic regions in follicular thyroid carcinomas and atypical adenomas. J Clin Endocrinol Metab; 2006 Jan;91(1):262-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of loss of heterozygosity in imprinted, compared with nonimprinted, genomic regions in follicular thyroid carcinomas and atypical adenomas.
  • DESIGN: In total, thyroid tissue was obtained from 72 patients with thyroid neoplasias comprising 34 follicular thyroid carcinomas (FTCs) and 38 follicular adenomas.
  • RESULTS: Overall LOH frequencies for the IR markers were 26% for the adenomas and 38% for the carcinomas.
  • In the NIR, the overall LOH frequency was 23 and 26% for adenomas and FTCs, respectively.
  • The difference in LOH frequencies between IR and NIR was statistically significant only for the carcinomas (P = 0.001), although there was a similar trend for the atypical adenomas (ATY, P = 0.06).
  • The fact that the ATY trended toward differential IR/NIR LOH, similar to FTC, may suggest that loss of IR might be instrumental in the adenoma-carcinoma sequence in thyroid carcinogenesis and that ATY could be an important intermediate in this pathway.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Papillary, Follicular / genetics. Genomic Imprinting. Loss of Heterozygosity / physiology. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249278.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P30CA16058
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


42. Ueda M, Miura Y, Kunihiro O, Ishikawa T, Ichikawa Y, Endo I, Sekido H, Togo S, Shimada H: MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT). Hepatogastroenterology; 2005 Mar-Apr;52(62):398-403
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
  • According to the WHO classification, there were 10 intraductal papillary-mucinous adenomas (IPMA); 3 borderline intraductal papillary-mucinous neoplasms (IPMB); 4 intraductal papillary-mucinous carcinomas (IPMC), non-invasive type (nIPMC); 4 IPMCs with invasive muci nous carcinoma (IPMC/muc); and 3 IPMCs with invasive tubular adenocarcinoma (IPMC/tub).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816444.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; 0 / MUC2 protein, human; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


43. El Demellawy D, Nasr AL, Babay S, Alowami S: Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. Pathol Res Pract; 2009;205(5):303-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
  • Diagnosis of papillary thyroid carcinoma (PTC), in many but not all cases, is an easily achievable diagnosis with almost minimal interobservable variability between pathologists.
  • A total of 185 cases were studied with tissues from 75 carcinomas (72 papillary, 2 follicular, 1 Hürthle cell) and 35 adenomas (32 follicular and 3 Hürthle cell) evaluated by immunohistochemistry for the expression of this marker.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Antigens, CD56 / metabolism. Biomarkers, Tumor / analysis. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153015.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor
  •  go-up   go-down


44. Nakagohri T, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kobayashi S, Kojima M, Miyauchi H, Asano T: Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms. J Hepatobiliary Pancreat Sci; 2010 Nov;17(6):798-802
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
  • BACKGROUND: Previous reports have suggested that patients with intraductal papillary mucinous neoplasm (IPMN) have a favorable prognosis after surgical resection.
  • RESULTS: There were 13 patients with noninvasive IPMNs (10 adenomas and 3 noninvasive carcinomas) and 2 patients with minimally invasive intraductal papillary mucinous carcinoma (minimally invasive IPMN).
  • Complete tumor removal (R0 resection) was performed in four patients (80%) with intraductal papillary mucinous carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727540.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


45. Murakami Y, Uemura K, Ohge H, Hayashidani Y, Sudo T, Sueda T: Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery; 2006 Sep;140(3):448-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma.
  • BACKGROUND: Intraductal papillary-mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) of the pancreas have similar clinicopathologic findings.
  • RESULTS: IPMNs consisted of 32 adenomas, 12 borderline neoplasms, 13 adenocarcinomas in situ, and 13 invasive adenocarcinomas; MCNs included 6 adenomas and 1 invasive adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surgery. 2007 Apr;141(4):545-6 [17383536.001]
  • (PMID = 16934608.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Michaels PJ, Brachtel EF, Bounds BC, Brugge WR, Pitman MB: Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade. Cancer; 2006 Jun 25;108(3):163-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.
  • BACKGROUND: Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized cystic neoplasm of the pancreas, histologically classified by the degree of epithelial atypia and by the presence or absence of invasion of the cyst wall.
  • RESULTS: The 34 cytology samples represented 4 adenomas, 15 IPMN-moderate dysplasias, 7 intraductal carcinomas, and 8 IPMNs with invasive carcinoma.
  • Gastrointestinal contamination did not appear to create diagnostic difficulty due to an apparent dual (dysplastic-nondysplastic) epithelial population, but only 4 adenomas were evaluated in this study.
  • Necrosis distinguished IPMN with carcinoma from IPMN-adenomas and IPMN with moderate dysplasia (P < .00001), and was more often observed with invasion than IPMN-carcinoma in situ (P < .05).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Mucins / metabolism. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550572.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


47. Tamahashi U, Kumagai J, Takizawa T, Sekine M, Eishi Y: Expression and intracellular localization of matrix metalloproteinases in intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch; 2008 Jul;453(1):79-87
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and intracellular localization of matrix metalloproteinases in intraductal papillary mucinous neoplasms of the pancreas.
  • To analyze the expression of matrix metalloproteinases (MMPs) and their relationships with the histological grades of the intraductal papillary mucinous neoplasm (IPMN) of the pancreas, we examined the frequency of expression and intracellular localization of MMP1, MMP2, MMP3, MMP7, and MMP9 in IPMN by immunohistochemistry.
  • A total of 45 IPMN lesions (14 adenomas, 17 borderline lesions, nine noninvasive carcinomas, and five invasive lesions) from 21 patients were examined.
  • Frequency of tumor cells expressing MMP7 was low in adenomas (median, 5.0%), higher in borderline lesions (median, 30.0%), in noninvasive carcinomas (median, 50.0%), and in invasive lesions (median, 80.0%), with a significant trend (P < 0.0001).
  • MMP7 may contribute to the process by which IPMN advances from adenoma to carcinoma and to subsequent invasion of tumor cells in IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenoma / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Papillary / metabolism. Matrix Metalloproteinases / metabolism. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500535.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


48. Letsas KP, Vartholomatos G, Tsepi C, Tsatsoulis A, Frangou-Lazaridis M: Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers? Neoplasma; 2007;54(1):57-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers?
  • Genetic analysis of the aspirates by RT-PCR may contribute, in parallel to the cytology report, to a more precise diagnosis.
  • A semi-quantitative RT-PCR assay was developed to determine prothymosin alpha and parathymosin mRNA expression patterns in thyroid follicular cells obtained from the fine-needle aspiration biopsy specimens of patients diagnosed with simple nodular goitre, follicular adenoma, papillary and follicular well-differentiated carcinomas.
  • Prothymosin alpha and parathymosin mRNA levels were found significantly elevated in well-differentiated carcinomas in relation to adenomas (p<0.05) and goitres (p<0.05), an event possibly linked to the proliferation activity of thyroid follicular cells.
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adult. Aged. Biomarkers / analysis. Biopsy, Fine-Needle / methods. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Proliferation. Diagnosis, Differential. Female. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction / methods. Thyroid Nodule / genetics. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203893.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Protein Precursors; 0 / RNA, Messenger; 0 / prothymosin alpha; 61512-21-8 / Thymosin; 95328-48-6 / parathymosin alpha
  •  go-up   go-down


49. Gupta R, Mortelé KJ, Tatli S, Girshman J, Glickman JN, Levy AD, Erturk SM, Heffess CS, Banks PA, Silverman SG: Pancreatic intraductal papillary mucinous neoplasms: role of CT in predicting pathologic subtypes. AJR Am J Roentgenol; 2008 Nov;191(5):1458-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic intraductal papillary mucinous neoplasms: role of CT in predicting pathologic subtypes.
  • OBJECTIVE: The objective of our study was to evaluate whether CT can be used to predict the pathologic subtypes of pancreatic intraductal papillary mucinous neoplasms (IPMNs).
  • MATERIALS AND METHODS: Three radiologists, blinded to the pathologic IPMN subtype, retrospectively and independently reviewed the preoperative CT scans of 38 patients with surgically resected pancreatic IPMN: 11 intraductal papillary mucinous adenomas, 11 intraductal papillary mucinous carcinomas, and 16 intraductal papillary mucinous carcinomas with invasion.
  • RESULTS: Predominant main pancreatic duct (MPD) involvement (p = 0.04) and a wide (> 1 cm) connection of a side-branch lesion with the MPD (p = 0.03) correlated with intraductal papillary mucinous carcinoma with invasion.
  • Tumor size, MPD diameter, number of tumors per patient, number of pseudoseptations per tumor, common bile duct dilatation, enlarged lymph nodes, intraductal calcifications, papillary bulging, and presence and size of a solid mass yielded no statistically significant relationship with pathologic subtype.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] AJR Am J Roentgenol. 2008 Dec;191(6):1876
  • (PMID = 18941085.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Erkiliç S, Koçer NE: The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves' disease. Endocr Pathol; 2005;16(1):63-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves' disease.
  • All types of thyroid cancers may co-exist with Graves' disease but papillary carcinoma is the most frequent.
  • Vesicular nuclei, nuclear grooves, and papillary formations that may be seen in Graves' disease may lead the pathologist to an overdiagnosis of papillary carcinoma.
  • The differential diagnosis between a true papillary carcinoma and foci mimicking papillary carcinoma in Graves' disease may be challenging by light microscopic features only.
  • This study is designed to determine whether CK19 is effective in the discrimination between the true papillary carcinoma of thyroid and foci resembling papillary carcinoma in Graves' disease.
  • Twenty-five cases with papillary carcinoma and 25 cases with Graves' disease containing foci resembling papillary carcinoma were included in the study.
  • All 25 cases with papillary carcinoma stained positive with CK19, whereas only six of 25 cases with Graves' disease showed weak staining, and the remaining 19 cases were completely negative.
  • It is known that CK19 may show faint staining in benign thyroid lesions such as adenomas.
  • Staining pattern with CK19 together with histopathological findings may be helpful in the differential diagnosis between foci mimicking papillary carcinoma and true papillary carcinoma in Graves' disease.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Graves Disease / diagnosis. Keratins / metabolism. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Graves' Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000848.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


51. Nellore A, Paziana K, Ma C, Tsygankova OM, Wang Y, Puttaswamy K, Iqbal AU, Franks SR, Lv Y, Troxel AB, Feldman MD, Meinkoth JL, Brose MS: Loss of Rap1GAP in papillary thyroid cancer. J Clin Endocrinol Metab; 2009 Mar;94(3):1026-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Rap1GAP in papillary thyroid cancer.
  • We previously reported Rap1GAP was highly expressed in normal human thyroid cells and decreased in five papillary thyroid carcinomas (PTCs).
  • OBJECTIVES: To confirm the significance of these findings, we analyzed Rap1GAP expression in a larger set of benign tumors (adenomas and hyperplastic nodules) and PTCs.
  • RESULTS: We observed that down-regulation of Rap1GAP in benign lesions and PTCs was common.
  • Approximately 20% of PTCs and adenomas exhibited allelic loss of Rap1GAP.
  • The more frequent and greater down-regulation of Rap1GAP in PTCs compared with adenomas suggests a role for Rap1GAP depletion in the progression of human thyroid tumors, possibly through unrestrained Rap activity.

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9064-9 [10922060.001]
  • [Cites] Mol Cell Proteomics. 2008 Oct;7(10):2019-27 [18669619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5418-23 [11959997.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3315-21 [12036950.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2649-57 [12750293.001]
  • [Cites] Trends Biochem Sci. 2003 May;28(5):267-75 [12765839.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):55-65 [12892713.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4561-7 [12907632.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5501-7 [14660640.001]
  • [Cites] Trends Cell Biol. 2004 Jul;14(7):377-85 [15246431.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(15):6690-700 [15254236.001]
  • [Cites] Cytogenet Cell Genet. 1994;66(1):18-21 [8275700.001]
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1752-7 [7712484.001]
  • [Cites] Oncogene. 1997 Feb 6;14(5):623-5 [9053862.001]
  • [Cites] J Biol Chem. 1997 Feb 28;272(9):5600-5 [9038168.001]
  • [Cites] J Med Genet. 1997 Aug;34(8):617-9 [9279750.001]
  • [Cites] Br J Cancer. 1997;76(5):594-9 [9303357.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):733-44 [9858596.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):46868-75 [15331589.001]
  • [Cites] J Cell Sci. 2005 Oct 15;118(Pt 20):4765-83 [16219685.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):898-906 [16424023.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):585-96 [16436672.001]
  • [Cites] J Cell Sci. 2007 Jan 1;120(Pt 1):17-22 [17182900.001]
  • [Cites] Mol Cell Biol. 2007 Oct;27(19):6647-58 [17646383.001]
  • [Cites] N Engl J Med. 2008 Jul 3;359(1):31-42 [18596272.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4714-9 [18541894.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4708-13 [18541897.001]
  • [Cites] Science. 2002 Feb 15;295(5558):1285-8 [11847339.001]
  • (PMID = 19066305.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109543; United States / NIDDK NIH HHS / DK / R01 DK055757; United States / NCI NIH HHS / CA / CA109543; United States / NIDDK NIH HHS / DK / DK55757
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GTPase-Activating Proteins; 0 / RAP1GAP protein, human; 0 / TERF2IP protein, human; 0 / Telomere-Binding Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Other-IDs] NLM/ PMC2681278
  •  go-up   go-down


52. Lü K, Dai Q, Xu ZH, Zhang YX, Tan L, Yuan Y, Jiang YX: Ultrasonographic characteristics of intraductal papillary mucinous neoplasm of the pancreas. Chin Med Sci J; 2010 Sep;25(3):151-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonographic characteristics of intraductal papillary mucinous neoplasm of the pancreas.
  • OBJECTIVE: To analyze the clinical and ultrasonographic imaging features of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • METHODS: Twelve patients with IPMN underwent surgery between May 2005 and December 2008, including 4 (33.3%) with adenoma and 8 (66.7%) with adenocarcinoma.
  • The mean diameters of the lesions were 1.4 +/- 0.8 cm (range, 0.5-2.0) and 6.3 +/- 6.0 cm (range, 2.0-20.0) in adenomas and adenocarcinomas, respectively.
  • And the mean diameters of the main duct in adenomas and adenocarcinomas were 1.0 +/- 0.8 cm and 1.6 +/- 1.0 cm, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21180276.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


53. Takahashi H, Nakamori S, Nakahira S, Tsujie M, Takahshi Y, Marubashi S, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M: Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas. Ann Surg Oncol; 2006 Jul;13(7):955-60
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas.
  • BACKGROUND: Noninvasive and minimally invasive intraductal papillary-mucinous neoplasms (IPMNs) have a favorable surgical outcome.
  • RESULTS: Of the 20 patients, 13 had benign IPMNs, including adenomas (n = 10) and borderlines (n = 3), and 7 had malignant IPMNs, including carcinomas in situ (n = 4) and minimally invasive IPMNs (n = 3).
  • All of the patients with benign IPMNs survived, whereas the 10-year survival rate of the patients with malignant IPMNs was 67%.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788757.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Szponar A, Zubakov D, Pawlak J, Jauch A, Kovacs G: Three genetic developmental stages of papillary renal cell tumors: duplication of chromosome 1q marks fatal progression. Int J Cancer; 2009 May 1;124(9):2071-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three genetic developmental stages of papillary renal cell tumors: duplication of chromosome 1q marks fatal progression.
  • Papillary renal cell tumors (RCT) make up a cytomorphologically and biologically heterogeneous group of kidney cancers including renal cell adenomas (RCA) and renal cell carcinomas (RCC).
  • To find genetic markers landmarking the tumor progression, we have evaluated the genetic alterations obtained by karyotyping, chromosomal and array-CGH and compared with the cytological characteristics and biological behavior of 60 papillary RCTs.
  • Based on the genetic and clinical data, we have separated 3 groups of tumors and proposed 3 genetically defined developmental stages of papillary RCTs.
  • Papillary RCAs are characterized by combined trisomy of chromosomes 7 and 17, whereas papillary RCCs displayed additional trisomies of 3q, 8q, 12q, 16q and 20q.
  • Therefore, we suggest that our genetic classification system landmarking papillary RCA, papillary RCC without and with progression offer a better system to characterize the tumor biology of clinical significance than a cellular/morphological classification.
  • [MeSH-major] Carcinoma, Papillary / genetics. Chromosomes, Human, Pair 1 / genetics. Gene Duplication. Kidney Neoplasms / genetics. Trisomy / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19123481.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Oncogene Proteins; 0 / RNA, Messenger; EC 2.7.1.- / NEK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.6.1.- / KIF14 protein, human; EC 3.6.1.- / Kinesin
  •  go-up   go-down


55. Castro P, Rebocho AP, Soares RJ, Magalhães J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P, Sobrinho-Simões M: PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab; 2006 Jan;91(1):213-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.
  • CONTEXT: The clinicopathological characteristics and the molecular features of the follicular variant of papillary thyroid carcinoma (FVPTC) remain controversial.
  • OBJECTIVE/DESIGN/PATIENTS: In an attempt to clarify such controversies and to find whether or not FVPTC cases share the molecular features of follicular tumors, we searched for the presence of PAX8-PPARgamma rearrangements, RAS mutations, and RAP-1, RAF-1, and BRAF mutations in a series of 40 FVPTCs as well as in 27 follicular thyroid carcinomas (FTCs) and 12 follicular thyroid adenomas (FTAs).
  • Fluorescence in situ hybridization and RT-PCR were used to detect the PAX8-PPARgamma rearrangement and PCR, single strand confirmational polymorphism, and sequencing for searching the mutations.
  • [MeSH-major] Carcinoma, Papillary, Follicular / genetics. PPAR gamma / genetics. Paired Box Transcription Factors / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219715.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


56. Puppin C, Fabbro D, Dima M, Di Loreto C, Puxeddu E, Filetti S, Russo D, Damante G: High periostin expression correlates with aggressiveness in papillary thyroid carcinomas. J Endocrinol; 2008 May;197(2):401-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High periostin expression correlates with aggressiveness in papillary thyroid carcinomas.
  • Periostin expression was evaluated by quantitative PCR and immunohistochemistry in normal thyroid tissues, papillary thyroid carcinomas (PTCs), follicular thyroid carcinomas (FTCs), and follicular adenomas (FAs).
  • [MeSH-major] Carcinoma, Papillary / chemistry. Cell Adhesion Molecules / genetics. Thyroid Neoplasms / chemistry. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434370.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / RNA, Messenger; 0 / Receptors, Thyrotropin; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


57. Sheu SY, Görges R, Ensinger C, Ofner D, Farid NR, Siffert W, Schmid KW: Different genotype distribution of the GNB3 C825T polymorphism of the G protein beta3 subunit in adenomas and differentiated thyroid carcinomas of follicular cell origin. J Pathol; 2005 Dec;207(4):430-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different genotype distribution of the GNB3 C825T polymorphism of the G protein beta3 subunit in adenomas and differentiated thyroid carcinomas of follicular cell origin.
  • To elucidate a possible role in the development and course of thyroid tumours of follicular cell origin, C825T polymorphism genotypes and allele frequencies were investigated in a series of adenomas and differentiated carcinomas.
  • Genotypes and the allele frequency of the Gbeta3 polymorphism were investigated in samples from 361 patients (all white Caucasians) with differentiated thyroid tumours of follicular cell origin [80 adenomas and 95 follicular (FTCs) and 186 papillary carcinomas (PTCs)].
  • Both the genotype distribution (p = 0.029) and the allele frequency (p = 0.028) of the adenoma group were statistically significantly different from those of the control group.
  • Thyroid adenomas also differed for both parameters significantly from FTCs (p = 0.042 and 0.033, respectively) and PTCs (0.0018 and 0.0081, respectively), whereas no statistical difference was noted between the FTC and PTC groups.
  • [MeSH-major] Adenoma / genetics. Heterotrimeric GTP-Binding Proteins / genetics. Polymorphism, Genetic. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / genetics. Carcinoma, Papillary, Follicular / genetics. Female. Gene Frequency. Genotype. Humans. Male. Middle Aged. Sex Distribution. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Pathological Society of Great Britain and Ireland.
  • (PMID = 16178055.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / G-protein beta3 subunit; EC 3.6.5.1 / Heterotrimeric GTP-Binding Proteins
  •  go-up   go-down


58. Tabriz HM, Adabi Kh, Lashkari A, Heshmat R, Haghpanah V, Larijani B, Tavangar SM: Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. Pathol Res Pract; 2009;205(2):83-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
  • INTRODUCTION: We aimed at assessing the significance of nm23 gene expression in papillary and follicular carcinomas, the two most common differentiated thyroid carcinomas.
  • MATERIALS AND METHODS: During a cross-sectional study, 173 paraffin blocks, including 131 papillary thyroid carcinomas, 12 follicular carcinomas and 30 follicular adenomas were stained with nm23 marker by immunohistochemistry method.
  • RESULTS: nm23 was positive in 40% of the follicular adenoma, 67.2% of the papillary carcinoma and 66.7% of the follicular carcinoma. p value was more than 0.05 in the assessment of the relationship between nm23 and all of the above-mentioned parameters in differentiated thyroid carcinomas. nm23 expression did not significantly differentiate between follicular adenoma and carcinoma.
  • Also, nm23 cannot be considered as a useful marker for the evaluation of invasion in differentiated thyroid carcinomas or in distinctions between follicular adenoma and carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Papillary / metabolism. Adenoma / metabolism. NM23 Nucleoside Diphosphate Kinases / biosynthesis. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996649.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NM23 Nucleoside Diphosphate Kinases; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down


59. Franzoni A, Dima M, D'Agostino M, Puppin C, Fabbro D, Loreto CD, Pandolfi M, Puxeddu E, Moretti S, Celano M, Bruno R, Filetti S, Russo D, Damante G: Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. Thyroid; 2009 Mar;19(3):247-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation.
  • The objective of this study was to evaluate PHB expression in normal thyroid tissues, thyroid follicular adenomas (FAs), and papillary thyroid carcinomas (PTCs).
  • METHODS: PHB expression was analyzed by immunohistochemistry, Western blot, and quantitative reverse transcription polymerase chain reaction (RT-PCR).
  • PHB mRNA and protein overexpression, as assessed by quantitative RT-PCR and Western blot, was noted only in PTCs bearing the BRAF(V600E) mutation.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Mutation / physiology. Proto-Oncogene Proteins B-raf / genetics. Repressor Proteins / biosynthesis. Repressor Proteins / genetics. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adult. Blotting, Western. Cell Line. DNA Primers. Female. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Gland / metabolism. Thyrotropin / biosynthesis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207009.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / prohibitin; 9002-71-5 / Thyrotropin; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


60. Nakayama S, Semba S, Maeda N, Matsushita M, Kuroda Y, Yokozaki H: Hypermethylation-mediated reduction of WWOX expression in intraductal papillary mucinous neoplasms of the pancreas. Br J Cancer; 2009 May 5;100(9):1438-43
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation-mediated reduction of WWOX expression in intraductal papillary mucinous neoplasms of the pancreas.
  • In this study, we examined WWOX expression in intraductal papillary mucinous neoplasm of the pancreas (IPMN) to assess the function of WWOX in pancreatic duct tumourigenesis using immunohistochemistry and methylation-specific polymerase chain reaction analysis.
  • Among 41 IPMNs including intraductal papillary mucinous adenomas (IPMAs) and intraductal papillary mucinous carcinomas (IPMCs), loss or reduced WWOX immunoreactivity was detected in 3 (15%) of 20 IPMAs and 17 (81%) of 21 IPMCs.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Carcinoma, Papillary / genetics. DNA Methylation / genetics. Gene Expression Regulation, Neoplastic. Oxidoreductases / deficiency. Oxidoreductases / genetics. Pancreatic Neoplasms / genetics. Suppression, Genetic. Tumor Suppressor Proteins / deficiency. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4222-6 [9766641.001]
  • [Cites] Jpn J Cancer Res. 1999 Feb;90(2):188-93 [10189889.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8256-61 [15548692.001]
  • [Cites] Oncogene. 2005 Feb 24;24(9):1625-33 [15674328.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22115-23 [15817471.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15611-6 [16223882.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):27-36 [16225988.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6477-81 [16818616.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3949-54 [17360458.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):242-8 [17097223.001]
  • [Cites] Cancer Sci. 2008 Jul;99(7):1370-6 [18460020.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):178-86 [19151715.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):37-43 [10623651.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1129-34 [11020896.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11417-22 [11572989.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1832-40 [11896615.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2258-60 [11956080.001]
  • [Cites] Pancreas. 2003 Apr;26(3):250-7 [12657951.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33571-82 [12794086.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4401-6 [15070730.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2459-65 [15073125.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3772-9 [15173084.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] J Biochem. 1998 Mar;123(3):492-8 [9538233.001]
  • (PMID = 19352382.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA, Single-Stranded; 0 / Tumor Suppressor Proteins; EC 1.- / Oxidoreductases; EC 1.1.1.- / WWOX protein, human
  • [Other-IDs] NLM/ PMC2694421
  •  go-up   go-down


61. Ishida M, Egawa S, Kawaguchi K, Aoki T, Sakata N, Mikami Y, Motoi F, Abe T, Fukuyama S, Katayose Y, Sunamura M, Unno M, Moriya T, Horii A, Furukawa T: Synchronous and metachronous extrapancreatic malignant neoplasms in patients with intraductal papillary-mucinous neoplasm of the pancreas. Pancreatology; 2008;8(6):577-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous and metachronous extrapancreatic malignant neoplasms in patients with intraductal papillary-mucinous neoplasm of the pancreas.
  • BACKGROUND/AIMS: Patients with intraductal papillary-mucinous neoplasm (IPMN) of the pancreas are likely to have a better prognosis than those with conventional pancreatic ductal adenocarcinoma.
  • RESULTS: The 61 patients with IPMN in this study comprised 25 with intraductal papillary-mucinous adenomas (IPMA) and 36 with intraductal papillary-mucinous carcinomas (IPMC) including 6 with invasive carcinomas.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 18824881.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


62. Chuang TC, Chuang AY, Poeta L, Koch WM, Califano JA, Tufano RP: Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck; 2010 Feb;32(2):229-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.
  • BACKGROUND.: An activating point mutation of the BRAF oncogene results in a V600E amino acid missense mutation found in a majority of papillary thyroid carcinomas (PTC).
  • METHODS.: In this study, 28 matched tumor and serum samples obtained from patients with both benign and malignant thyroid disorders were analyzed for BRAF mutation using a gap-ligase chain reaction technique.
  • RESULTS.: The BRAF mutation was absent in tumor DNA samples obtained from patients with benign adenomas, follicular neoplasms or carcinoma, and thyroid lymphoma.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Papillary, Follicular / genetics. DNA, Neoplasm / genetics. Proto-Oncogene Proteins B-raf / blood. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley Periodicals, Inc.
  • (PMID = 19626635.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / 1R01DE015939-01; United States / NCI NIH HHS / CA / P50 CA96784
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


63. Maciel RM, Kimura ET, Cerutti JM: [Pathogenesis of differentiated thyroid cancer (papillary and follicular)]. Arq Bras Endocrinol Metabol; 2005 Oct;49(5):691-700
SciCrunch. HGNC: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathogenesis of differentiated thyroid cancer (papillary and follicular)].
  • Differentiated thyroid cancers (papillary--PTC and follicular--FTC) are the most common endocrine malignancies.
  • A chromosomal translocation between the transcription factor PAX8 and the peroxisome proliferator-activated receptorgamma (PPARgamma) occurs in 30-50% of patients; however, the presence of PAX8-PPARgamma is also demonstrated in follicular adenomas.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma, Papillary / genetics. Gene Rearrangement / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics. Thyroid Neoplasms / genetics


64. Naoi Y, Miyoshi Y, Taguchi T, Kim SJ, Arai T, Maruyama N, Tamaki Y, Noguchi S: Connexin26 expression is associated with aggressive phenotype in human papillary and follicular thyroid cancers. Cancer Lett; 2008 Apr 18;262(2):248-56
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Connexin26 expression is associated with aggressive phenotype in human papillary and follicular thyroid cancers.
  • In the study presented here, we investigated Cx26 expression in human papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) and its relationship with various clinicopathological parameters.
  • Of 69 PTCs, 33 were positive for Cx26 (47.8%), as were five of 11 FTCs (45.5%), all follicular thyroid adenomas (n=22) and normal thyroid tissues (n=20) were negative for Cx26.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Papillary / genetics. Connexins / genetics. Thyroid Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18191019.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Connexins; 127120-53-0 / connexin 26
  •  go-up   go-down


65. Tena-Suck ML, Salinas-Lara C, Sánchez-García A, Rembao-Bojórquez D, Ortiz-Plata A: Late development of intraventricular papillary pituitary carcinoma after irradiation of prolactinoma. Surg Neurol; 2006 Nov;66(5):527-33; discussion 533
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late development of intraventricular papillary pituitary carcinoma after irradiation of prolactinoma.
  • BACKGROUND: Intracranial dissemination of pituitary adenomas is a rare event that does not equate malignancy.
  • A case of papillary pituitary carcinoma developed 12 years after radiotherapy for prolactin-secreting hormone pituitary adenoma is presented.
  • CONCLUSIONS: The tumor was considered a primary pituitary papillary carcinoma.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Cerebral Ventricle Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Pituitary Neoplasms / diagnosis. Prolactinoma / diagnosis. Radiotherapy / adverse effects

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084204.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


66. Sheu SY, Vogel E, Worm K, Grabellus F, Schwertheim S, Schmid KW: Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma. Histopathology; 2010 Apr;56(5):632-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
  • AIMS: To compare the expression pattern of five microRNAs (miRNAs) (146b, -181b, -21, -221, -222) of papillary thyroid carcinoma (PTC) and hyalinizing trabecular tumour of the thyroid (HTT).
  • METHODS AND RESULTS: The expression pattern of five miRNAs known to be up-regulated in PTC was retrospectively analysed in 18 HTTs, adjacent normal thyroid tissue, 10 PTCs, 10 follicular adenomas and 10 non-toxic multinodular goitres (MNG) by reverse transcriptase-polymerase chain reaction using the TaqMan miRNA assay.
  • All miRNAs were significantly up-regulated in PTCs, whereas all miRNAs in HTT, normal thyroid tissue, adenomas, and MNGs were down-regulated.
  • It is suggested that HTTs lacking both a miRNA expression pattern characteristic for PTC and RET/PTC rearrangements are re-designated as 'hyalinizing trabecular adenomas'.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Adenoma / genetics. MicroRNAs / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459574.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / ret-PTC fusion oncoproteins, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


67. Li T, Fan J, Hu SY, Tang ZY, Zhi XT: [A clinicopathologic study of biliary intraductal papillary neoplasm]. Zhonghua Wai Ke Za Zhi; 2010 Apr 1;48(7):488-91
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinicopathologic study of biliary intraductal papillary neoplasm].
  • OBJECTIVE: To investigate the clinicopathologic features, diagnosis and treatment of biliary intraductal papillary neoplasm (IPN-B).
  • Histopathologically, there were 4 adenomas, 1 borderline neoplasm, 6 carcinomas in situ, and 12 carcinomas.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Carcinoma, Papillary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646655.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


68. Zhu XL, Zhou XY, Zhang TM, Zhu XZ: [Expressions of wildtype-RET and RET/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation]. Zhonghua Bing Li Xue Za Zhi; 2006 Feb;35(2):87-91
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of wildtype-RET and RET/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation].
  • OBJECTIVE: To evaluate the expressions of wildtype-RET (WT-RET) and RET/PTC in sporadic adult papillary thyroid carcinoma and to investigate their clinicopathologic correlation.
  • METHODS: Sixty-six papillary thyroid carcinomas (PTC) and thirty-six control cases with frozen and paraffin-embedded tissues were analyzed for the expressions of WT-RET and oncogene RET/PTC1 or RET/PTC3 by nested RT-PCR. RESULTS:.
  • One of eight adenomas (12.5 %) expressed wild-type RET (WT-RET). (3) Fourteen PTCs (21.2%) expressed RET/PTC, including five cases expressing RET/PTC1 and nine cases expressing RET/PTC3.
  • The expression patterns of WT-RET in PTC and adenoma suggest that there are different molecular mechanisms in activating RET proto-oncogene in thyroid tumors.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Gene Rearrangement. Oncogene Proteins, Fusion / biosynthesis. Protein-Tyrosine Kinases / biosynthesis. Proto-Oncogene Proteins c-ret / biosynthesis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adolescent. Adult. Aged. Female. Hashimoto Disease / metabolism. Humans. Lymphatic Metastasis. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630482.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / ret-PTC fusion oncoproteins, human
  •  go-up   go-down


69. Koizumi K, Fujii T, Matsumoto A, Sugiyama R, Suzuki S, Sukegawa R, Ozawa K, Orii F, Taruishi M, Saitoh Y, Sotokawa M, Takada A: [Synchronous double invasive ductal carcinomas of the pancreas with multifocal branch duct intraductal papillary mucinous neoplasms of the pancreas]. Nihon Shokakibyo Gakkai Zasshi; 2009 Jan;106(1):98-105
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous double invasive ductal carcinomas of the pancreas with multifocal branch duct intraductal papillary mucinous neoplasms of the pancreas].
  • Final histological diagnosis was double invasive ductal carcinomas of the pancreas head and tail with multifocal branch duct intraductal papillary mucinous adenomas of the pancreas.
  • The present case suggests that entire pancreas might have malignant potential in patients with intraductal papillary mucinous neoplasms.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Neoplasms, Multiple Primary. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122428.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Cassol CA, Guo M, Ezzat S, Asa SL: GNAq mutations are not identified in papillary thyroid carcinomas and hyperfunctioning thyroid nodules. Endocr Pathol; 2010 Dec;21(4):250-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GNAq mutations are not identified in papillary thyroid carcinomas and hyperfunctioning thyroid nodules.
  • Additionally, activating mutations of another subtype of G protein (GNAS1) are frequently found in hyperfunctioning thyroid adenomas, making it plausible that GNAq-activating mutations could also be found in some of these nodules.
  • To investigate thyroid papillary carcinomas and thyroid hyperfunctioning nodules for GNAq mutations in exon 5, codon 209, a total of 32 RET/PTC, BRAF, and RAS negative thyroid papillary carcinomas and 13 hyperfunctioning thyroid nodules were evaluated.
  • Although plausible, GNAq mutations seem not to play an important role in the development of thyroid follicular neoplasms, either benign hyperfunctioning nodules or malignant papillary carcinomas.
  • Our results are in accordance with the literature, in which no GNAq hotspot mutations were found in thyroid papillary carcinomas, as well as in an extensive panel of other tumors.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Papillary / genetics. GTP-Binding Protein alpha Subunits / genetics. Mutation. Thyroid Neoplasms / genetics. Thyroid Nodule / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20714830.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GNAQ protein, human; 0 / GTP-Binding Protein alpha Subunits
  •  go-up   go-down


71. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Sueda T: Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas. J Gastrointest Surg; 2007 Mar;11(3):338-44
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas.
  • The aim of this study was to identify useful preoperative diagnostic findings indicative of malignant or invasive intraductal papillary-mucinous neoplasms (IPMN) of the pancreas to determine an optimal operative procedure for IPMN.
  • Sixty-two IPMNs, which consisted of 29 adenomas, 10 borderline tumors, 11 adenocarcinomas in situ, and invasive adenocarcinomas were reviewed from 1990 to 2003.
  • There was no recurrent disease in patients with adenoma and adenocarcinoma in situ, whereas recurrences occurred in 6 of 12 patients with invasive IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17458608.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Schoedel KE, Finkelstein SD, Ohori NP: K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. Diagn Cytopathol; 2006 Sep;34(9):605-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas.
  • Intraductal papillary mucinous neoplasms (IPMNs) represent a subset of preinvasive pancreatic cystic neoplasms and are associated with accumulated genetic mutations, especially K-ras and tumor suppressor genes such as p53.
  • All patients subsequently underwent surgical resection of the pancreas and IPMN was documented in all (6 adenomas, 6 borderline tumors, and 4 carcinomas).
  • LOH was observed in 3 of 4 carcinomas as compared to 4 of 11 adenomas and borderline lesions (1 was QNS).
  • LOH and K-ras mutations were both acquired in 2 of 4 carcinomas and in 1 of 12 adenoma/borderline lesions.
  • Increasing degree of neoplasia appears to correlate with increased genetic abnormality using a panel of selected genomic markers.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Biomarkers, Tumor / genetics. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Papillary / genetics. Microsatellite Repeats. Pancreatic Neoplasms / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16900481.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


73. Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, Fenzi G, Vitale M: Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol; 2006 Feb;154(2):341-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA).
  • OBJECTIVE: The somatic point mutation in the BRAF gene, which results in a valine-to-glutamate substitution at residue 600 (BRAF(V600E)), is an ideal hallmark of papillary thyroid carcinoma (PTC).
  • Then, we used MASA 78 to analyze 78 archival thyroid tissues, including normal samples, follicular adenomas, follicular carcinomas and PTC.
  • No mutations of BRAF were detected in the normal thyroid tissues, nor in follicular adenomas or follicular carcinomas.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452550.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


74. Böör A, Jurkovic I, Havierová Z, Kocan P: Prolonged treatment of chronic renal insufficiency, acquired cystic kidney disease, simultaneous precancerous lesions and multiple tumors of left kidney. Cesk Patol; 2010 Oct;46(4):105-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy revealed acquired cystic kidney disease associated with multiple precancerous lesions, several small papillary adenomas and a multifocal renal cell carcinoma with conventional and papillary structures with admixture of small foci of highly cellular sarcomatoid features.
  • PRINCIPAL CONCLUSIONS: This case illustrates the association of chronic renal insufficiency, uremic oxalosis, long-term hemodialysis, acquired cystic kidney disease and development of variable precursor intratubular and intracystic lesions progressing to several papillary adenomas and multifocal renal cell carcinomas with variegated microscopic structures in one kidney.


75. Ito H, Endo T, Oka T, Matumoto T, Abe T, Toyota M, Imai K, Satoh M, Maguchi H, Shinohara T: Mucin expression profile is related to biological and clinical characteristics of intraductal papillary-mucinous tumors of the pancreas. Pancreas; 2005 May;30(4):e96-102
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin expression profile is related to biological and clinical characteristics of intraductal papillary-mucinous tumors of the pancreas.
  • OBJECTIVES: Biologic and clinical characteristics of intraductal papillary-mucinous tumors of the pancreas (IPMTs) were studied in reference to immunohistochemical mucin (MUC1, MUC2, and MUC5AC) expression.
  • METHODS: Histologic grade, immunohistochemical ki-67 and p53 expression, and findings in imaging tests of 21 IPMTs (9 carcinomas, 6 borderline tumors, and 6 adenomas) were examined according to the mucin expression profile.
  • Morphologic changes in imaging tests during the observation periods were most remarkable in the M1 group.
  • CONCLUSIONS: Our results suggest that MUC1 is related to malignant character but MUC5AC alone is related to benign character in IPMTs and that malignant potential of IPMTs expressing MUC2 depends on the degree of MUC2 expression.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Carcinoma, Papillary / metabolism. Mucins / metabolism. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841035.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


76. Yang AD, Melstrom LG, Bentrem DJ, Ujiki MB, Wayne JD, Strouch M, Bell RH, Rao SM, Talamonti MS: Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience. Surgery; 2007 Oct;142(4):529-34; discussion 534-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience.
  • PURPOSE: To evaluate the experience with pancreatectomy for intraductal papillary mucinous neoplasm (IPMN) at a single academic institution.
  • Nine patients had adenomas, 14 had borderline neoplasms, 10 had carcinoma in situ, and 9 had invasive carcinoma.
  • The 5-year disease-specific survival for patients with benign lesions was 100%, and 61% for patients with malignant lesions (P = .02).
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / statistics & numerical data. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950345.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Albores-Saavedra J, Hernandez M, Sanchez-Sosa S, Simpson K, Angeles A, Henson DE: Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroglobulin inclusions. Am J Surg Pathol; 2007 May;31(5):729-36
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroglobulin inclusions.
  • We describe the histologic variants of papillary and follicular carcinomas associated with 109 spindle and giant cell carcinomas (SGCC) of the thyroid and determine the incidence of rhabdoid and thyroglobulin inclusions in these tumors.
  • In addition, we searched for rhabdoid and thyroglobulin inclusions in 120 papillary carcinomas (PC) (all 15 variants included), 23 differentiated follicular carcinomas (DFC), (6 with insular pattern), 6 poorly differentiated follicular carcinomas (PDFC) and 34 follicular adenomas (FA).
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Giant Cell / pathology. Carcinoma, Papillary, Follicular / pathology. Inclusion Bodies / pathology. Rhabdoid Tumor / pathology. Thyroglobulin / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460457.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


78. Miyasaka Y, Nagai E, Yamaguchi H, Fujii K, Inoue T, Ohuchida K, Yamada T, Mizumoto K, Tanaka M, Tsuneyoshi M: The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res; 2007 Aug 1;13(15 Pt 1):4371-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas.
  • PURPOSE: Intraductal papillary mucinous neoplasms (IPMN) are known to show a transition from adenoma to carcinoma accompanied by several molecular abnormalities.
  • EXPERIMENTAL DESIGN: One hundred and twenty-eight IPMNs were classified into four groups (intraductal papillary mucinous adenoma, borderline IPMN, noninvasive intraductal papillary mucinous carcinoma, and invasive intraductal papillary mucinous carcinoma) and stained immunohistochemically using antibody for Thr(68)-phosphorylated Chk2.
  • RESULTS: Chk2 phosphorylation was shown in all adenomas and showed a significant decreasing trend with the progression of atypia (P < 0.0001 by the Cochran-Armitage test for trend).
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Cell Cycle Proteins / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. DNA Damage. DNA-Binding Proteins / metabolism. Pancreatic Neoplasms / metabolism. Protein-Serine-Threonine Kinases / metabolism. Signal Transduction. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671118.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


79. Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C, Orgiazzi J, Borson-Chazot F, Dante R, Rousset B: Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab; 2005 May;90(5):3028-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas.
  • SLC5A8 expression, unlike that of SLC5A5 and SLC26A4, was not regulated by TSH in normal human thyrocytes in culture and was not related to the functional state of thyroid tissue; toxic adenomas and adjacent resting tissues exhibited the same SLC5A8 transcript content.
  • SLC5A8 expression was selectively down-regulated (40-fold) in papillary thyroid carcinomas of classical form (PTC-cf.).
  • Methylation-specific PCR analyses showed that SLC5A8 was methylated in 90% of PTC-cf. and in about 20% of other papillary thyroid carcinomas.
  • [MeSH-major] Carcinoma, Papillary / genetics. Cation Transport Proteins / genetics. Gene Silencing. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15687339.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotide Translocator 2; 0 / Cation Transport Proteins; 0 / Membrane Transport Proteins; 0 / SLC26A4 protein, human; 0 / SLC5A8 protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


80. Hong SP, Lee EK, Park JY, Jeon TJ, Bang S, Park S, Chung JB, Lee WJ, Kim H, Song SY: Cripto-1 overexpression is involved in the tumorigenesis of gastric-type and pancreatobiliary-type intraductal papillary mucinous neoplasms of the pancreas. Oncol Rep; 2009 Jan;21(1):19-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cripto-1 overexpression is involved in the tumorigenesis of gastric-type and pancreatobiliary-type intraductal papillary mucinous neoplasms of the pancreas.
  • However, Cripto-1 expression in intraductal papillary mucinous neoplasms (IPMNs) has yet to be reported.
  • Cripto-1 expression was evaluated by immunohistochemistry using 37 IPMN tissue samples and real-time RT-PCR analysis of seven frozen samples.
  • Cripto-1 was positively stained in 3 of 4 (75%) adenomas, 12 of 19 (63.2%) borderline neoplasms, 5 of 11 (45.5%) non-invasive carcinomas and 2 of 3 (66.7%) invasive carcinomas.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adult. Aged. Female. GPI-Linked Proteins. Gene Expression. Humans. Immunohistochemistry. Intercellular Signaling Peptides and Proteins. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082438.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


81. Tienari J, Lehtonen S, Lehtonen E: CD2-associated protein in human urogenital system and in adult kidney tumours. Virchows Arch; 2005 Apr;446(4):394-401
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Type-I papillary RCCs (n=4) and papillary adenomas (n=3) were negative.
  • The results show that CD2AP displays a specific expression pattern in human urogenital organs and that distinct expression is shown in several types of kidney tumours but not in type-I papillary RCCs or in papillary adenomas.
  • [MeSH-major] Adenoma / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Proteins / metabolism. Urogenital System / metabolism. src Homology Domains / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785926.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / CD2-associated protein; 0 / Cytoskeletal Proteins; 0 / Proteins
  •  go-up   go-down


82. Pickett CA, Agoff SN, Widman TJ, Bronner MP: Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications. Thyroid; 2005 May;15(5):461-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications.
  • We have investigated the expression of cyclins D1 and E and of cyclin-dependent kinase inhibitor's p21 and p27 in papillary thyroid cancer (PTC) and correlated this with clinical/histological stage at diagnosis and with clinical outcome.
  • PTCs were compared to normal thyroid, adenomas, and undifferentiated thyroid cancers (UTCs).
  • Our studies indicate that PTCs and UTCs demonstrate low nuclear expression of cyclin E and p27, allowing a clear distinction between adenomas and these carcinomas (p < 0.004).
  • These studies suggest that evaluation of a panel of these markers and attention to their subcellular localization may be a useful adjunct in differentiating benign from malignant thyroid neoplasms and in predicting tumor behavior.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Cell Cycle / physiology. Cyclins / biosynthesis. Thyroid Neoplasms / metabolism

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929668.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


83. Kashima K, Ohike N, Mukai S, Sato M, Takahashi M, Morohoshi T: Expression of the tumor suppressor gene maspin and its significance in intraductal papillary mucinous neoplasms of the pancreas. Hepatobiliary Pancreat Dis Int; 2008 Feb;7(1):86-90
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the tumor suppressor gene maspin and its significance in intraductal papillary mucinous neoplasms of the pancreas.
  • We examined maspin expression immunohistochemically and assessed its significance in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • METHODS: We examined 39 surgically resected specimens of IPMN that included 17 adenomas (IPMAs), 5 borderline tumors (IPMBs), 4 non-invasive carcinomas (non-invasive IPMCs), and 13 invasive carcinomas (invasive IPMCs).
  • CONCLUSIONS: Maspin was expressed at high levels in IPMNs at various stages from adenoma to invasive carcinoma, and our results suggest that maspin may be involved in the occurrence and progression of IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenoma / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Pancreatic Neoplasms / metabolism. Serpins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234645.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


84. He CN, He L, Cheng JQ, Chen SC, Zhao HF, Zhai JP, Zhang J: [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis]. Zhonghua Bing Li Xue Za Zhi; 2008 Jan;37(1):35-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
  • OBJECTIVE: To study Twist expression in thyroid papillary carcinoma (PTC) by immunohistochemistry and to assess its usefulness as marker in the differential diagnosis of PTC, follicular adenomas (FA) and benign papillary lesions (BPL).
  • [MeSH-major] Carcinoma, Papillary / metabolism. Carcinoma, Papillary, Follicular / metabolism. Nuclear Proteins / metabolism. Thyroid Neoplasms / metabolism. Twist Transcription Factor / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Papillary / pathology. Adenoma / diagnosis. Adenoma / metabolism. Biomarkers, Tumor / immunology. Diagnosis, Differential. Galectin 3 / genetics. Galectin 3 / metabolism. Immunohistochemistry. Keratin-19 / genetics. Keratins / genetics. Keratins / metabolism. Thyroid Nodule / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509983.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19; 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Twist Transcription Factor; 68238-35-7 / Keratins
  •  go-up   go-down


85. Handra-Luca A, Fléjou JF, Rufat P, Corcos O, Belghiti J, Ruszniewski P, Degott C, Bedossa P, Couvelard A: Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma. Histopathology; 2006 Jun;48(7):813-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma.
  • AIMS: To examine cytokeratin, epithelial glycoprotein (mucin) and glycoprotein CD10 expression in benign mucinous cystdenomas (MCAs) in comparison with intraductal papillary mucinous adenomas (IPMAs).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / pathology. Cystadenoma, Mucinous / pathology. Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16722930.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


86. Kim SY, Lee JM, Kim SH, Shin KS, Kim YJ, An SK, Han CJ, Han JK, Choi BI: Macrocystic neoplasms of the pancreas: CT differentiation of serous oligocystic adenoma from mucinous cystadenoma and intraductal papillary mucinous tumor. AJR Am J Roentgenol; 2006 Nov;187(5):1192-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrocystic neoplasms of the pancreas: CT differentiation of serous oligocystic adenoma from mucinous cystadenoma and intraductal papillary mucinous tumor.
  • OBJECTIVE: The purpose of our study was to determine useful CT criteria for differentiating serous oligocystic adenomas of the pancreas from other similarly presenting neoplasms, such as mucinous cystadenoma and intraductal papillary mucinous tumor of the branch duct type.
  • MATERIALS AND METHODS: Forty-one patients with histologically confirmed macrocystic neoplasms of the pancreas were enrolled: serous oligocystic adenoma in 10 patients, mucinous cystadenoma in 13, and intraductal papillary mucinous tumor in 18.
  • RESULTS: Significant differences in lesion shape were found between serous oligocystic adenoma and the other macrocystic neoplasms (mucinous cystadenoma [p < 0.05], intraductal papillary mucinous tumor [p < 0.05]).
  • Serous oligocystic adenoma had a multicystic or lobulated contour with or without septation, whereas mucinous cystadenoma had a smooth contour with or without septation and intraductal papillary mucinous tumor had either a pleomorphic or a clubbed fingerlike cystic shape.
  • Serous oligocystic adenoma showed proximal MPD dilatation from the lesion, whereas intraductal papillary mucinous tumor showed distal or whole MPD dilatation (p < 0.05).
  • CONCLUSION: Serous oligocystic adenoma of the pancreas has characteristic CT findings that differentiate it from other cystic tumors.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056905.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Castro P, Roque L, Magalhães J, Sobrinho-Simões M: A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation. Int J Surg Pathol; 2005 Jul;13(3):235-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation.
  • The occurrence of the PAX8-PPARgamma fusion gene is thought to be restricted to follicular tumors (adenomas and carcinomas) of the thyroid (FTA and FTC).
  • Using interphase fluorescent in situ hybridization (FISH), together with recombinant tissue-type polymerase chain reaction (RT-PCR) and immunohistochemistry, we detected the PAX8-PPARgamma translocation in 4 of 8 cases of the follicular variant of papillary thyroid carcinoma (FVPTC) exclusively or almost exclusively (>95%) composed of follicles.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. PPAR gamma / genetics. Thyroid Neoplasms / genetics. Trans-Activators / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086077.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / PAX8 Transcription Factor; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Trans-Activators
  •  go-up   go-down


88. Hébrant A, van Staveren WC, Delys L, Solís DW, Bogdanova T, Andry G, Roger P, Dumont JE, Libert F, Maenhaut C: Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression. Exp Cell Res; 2007 Sep 10;313(15):3276-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression.
  • Constitutive activation of the RAS/RAF/MAPK pathway has been found in different tumor types including papillary thyroid carcinomas (PTCs).
  • Comparison of these two types of cells with cAMP activated cells, from thyroid-stimulating hormone-treated thyrocytes and autonomous adenomas, showed distinct gene expression profiles for the two pathways.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Cell Transformation, Neoplastic / metabolism. Epidermal Growth Factor / pharmacology. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Exp Cell Res. 2007 Nov 15;313(19):4082
  • (PMID = 17689531.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 62229-50-9 / Epidermal Growth Factor; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


89. Pan CC, Epstein JI: Detection of chromosome copy number alterations in metanephric adenomas by array comparative genomic hybridization. Mod Pathol; 2010 Dec;23(12):1634-40
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of chromosome copy number alterations in metanephric adenomas by array comparative genomic hybridization.
  • Metanephric adenoma is a rare benign renal tumor typically found in adults.
  • In this study, we investigated the genomic profile of nine cases of metanephric adenoma using array comparative genomic hybridization.
  • We did not observe consistent gains of chromosomes 7 and 17, which are common in papillary renal cell carcinoma, neither did we find chromosomal alterations frequently present in Wilms' tumors, including chromosome gains of 1q, 7q, and 12, and losses of 11p and 16q.
  • Our series demonstrates that the genetic profile of metanephric adenoma is fundamentally distinct from those of papillary renal cell carcinoma and Wilms' tumor.
  • [MeSH-major] Adenoma / genetics. Kidney Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20802469.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


90. Hirono S, Tani M, Kawai M, Ina S, Nishioka R, Miyazawa M, Fujita Y, Uchiyama K, Yamaue H: Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors. Arch Surg; 2009 Apr;144(4):345-9; discussion 349-50
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
  • BACKGROUND: Noninvasive intraductal papillary mucinous neoplasms (IPMNs) have a favorable prognosis; however, the prognosis of invasive intraductal papillary mucinous carcinoma (invasive IPMC) is poor.
  • Identification of predictive factors for differentiating IPMC from benign IPMNs would assist in providing appropriate treatment.
  • PATIENTS: Fifty-four patients with IPMN who underwent surgery; histologic examination showed benign adenomas in 29, carcinoma in situ in 14, and invasive carcinoma in 11 patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19380648.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Hopper AD, Bourke MJ, Williams SJ, Swan MP: Giant laterally spreading tumors of the papilla: endoscopic features, resection technique, and outcome (with videos). Gastrointest Endosc; 2010 May;71(6):967-75
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Successful endoscopic treatment of conventional papillary adenomas is well described.
  • INTERVENTION: Pre-resection staging and single-session endoscopic removal of papillary adenomas.
  • MAIN OUTCOME MEASUREMENTS: Technical success, complications, and adenoma recurrence for single-session removal of LST-P.
  • Outcomes were compared with those of conventional ampullary adenoma resection during the same period.
  • RESULTS: Twenty-five patients with ampullary adenomas were referred.
  • In 10 patients identified with LST-P (mean age 70.2 years; adenoma size 30-80 mm), combination EMR and papillectomy was performed in a single session.
  • Adenoma recurrence at 3 months was found in 1 patient (10%).
  • Complication and recurrence rates in smaller (<30 mm) ampullary adenoma resections were not significantly different.
  • In experienced hands, the outcomes are comparable to those for conventional ampullary adenomas.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / surgery. Ampulla of Vater. Duodenal Neoplasms / diagnosis. Duodenal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • [CommentIn] Endoscopy. 2011 Jan;43(1):42-6 [21234840.001]
  • (PMID = 20226451.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Sibio S, Borrini F, Sammartino P, Accarpio F, Biacchi D, Caprio G, Iafrate F, Baccheschi AM, Cornali T, Di Giorgio A: Predominant Brenner tumor combined with struma ovarii containing a papillary microcarcinoma associated with benign peritoneal strumosis: report of a case and histologic features. Endocr Pathol; 2010 Sep;21(3):199-203
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predominant Brenner tumor combined with struma ovarii containing a papillary microcarcinoma associated with benign peritoneal strumosis: report of a case and histologic features.
  • Brenner tumor and struma ovarii, two uncommon ovarian tumors arising alone or together with dermoid cysts or adenomas, are both rare entities.
  • The mass consisted predominantly of a Brenner tumor associated with struma ovarii containing a single small island of thyroid tissue that had undergone malignant transformation into a well-differentiated papillary carcinoma and also normal thyroid tissue that had spread to the peritoneum.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Papillary / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. Struma Ovarii / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20532676.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Kunisaki SM, Hertl M, Bodner BE, Cosimi AB: Mirizzi syndrome secondary to an adenoma of the cystic duct. J Hepatobiliary Pancreat Surg; 2005;12(2):159-62
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mirizzi syndrome secondary to an adenoma of the cystic duct.
  • Bile duct adenomas are uncommon lesions that can cause obstructive jaundice.
  • We report the unusual case of a 54-year-old man who developed Mirizzi syndrome secondary to a bile duct papillary adenoma located in the cystic duct remnant.
  • A case report is presented, together with a review of extrahepatic bile duct adenomas published in the English-language literature, with special attention directed toward the clinical manifestations, locations, and prognosis of these tumors.
  • Bile duct adenomas are very rare tumors.
  • We describe here a very rare, acalculous variant of Mirizzi syndrome secondary to a solitary papillary adenoma of the cystic duct.
  • In general, bile duct adenomas are uncommon lesions that are difficult to diagnoses preoperatively.
  • [MeSH-major] Adenoma / complications. Bile Duct Neoplasms / complications. Cholestasis / etiology. Cystic Duct

  • Genetic Alliance. consumer health - Mirizzi syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868083.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 28
  •  go-up   go-down


94. Sheu SY, Grabellus F, Schwertheim S, Worm K, Broecker-Preuss M, Schmid KW: Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br J Cancer; 2010 Jan 19;102(2):376-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours.
  • BACKGROUND: Recent studies showed a significant upregulation of distinct microRNAs (miRNAs) in papillary thyroid carcinoma (PTC).
  • METHODS: We used total RNA of 113 formalin-fixed paraffin-embedded tissues of 50 PTCs ((10 conventional type (PTC-CT), 10 tall cell variants (PTC-TCVs), 30 follicular variants (PTC-FVs)), 10 follicular adenomas (FAs), 10 multinodular goitres (MNGs), 21 follicular thyroid carcinomas and 22 well-differentiated tumours of unknown malignant potential (WDT-UMP) to analyse the miRNA expression pattern of five selected miRNAs (146b, 181b, 21, 221 and 222) using RT-PCR TaqMan miRNA assay to explore the diagnostic utility of this method.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / genetics. MicroRNAs / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Adult. Aged. Female. Gene Expression Profiling. Goiter, Nodular / genetics. Goiter, Nodular / pathology. Humans. Male. Middle Aged. Thyroid Diseases / genetics. Thyroid Diseases / pathology. Up-Regulation

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Horm Metab Res. 2009 Jun;41(6):475-81 [19370508.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1690-4 [9135009.001]
  • [Cites] Ann Surg. 1953 Jul;138(1):33-8 [13058300.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):245-62 [15947100.001]
  • [Cites] Virchows Arch. 2005 Jun;446(6):589-95 [15902486.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):216-22 [16434896.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2537-45 [16331254.001]
  • [Cites] Endocr Pathol. 2005 Winter;16(4):279-83 [16627915.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):497-508 [16728577.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6 [16885212.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2745-52 [12788883.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4267-71 [15356020.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3584-91 [16822819.001]
  • [Cites] Mol Cancer. 2006;5:24 [16784538.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):779-87 [17464312.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2007 Jul;51(5):843-51 [17891249.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Nov;92(11):4085-90 [17785355.001]
  • [Cites] APMIS. 2007 Oct;115(10):1090-106 [18042145.001]
  • [Cites] Oncogene. 2007 Nov 29;26(54):7590-5 [17563749.001]
  • [Cites] Endocr Pathol. 2007 Fall;18(3):163-73 [18058265.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1600-8 [18270258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 20;105(20):7269-74 [18474871.001]
  • [Cites] Mod Pathol. 2008 Sep;21(9):1139-46 [18587330.001]
  • [Cites] Oncogene. 2009 Jan 8;28(1):73-84 [18850008.001]
  • [Cites] Horm Metab Res. 2009 Jun;41(6):482-7 [19370505.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):279-87 [15505528.001]
  • (PMID = 20029416.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2816660
  •  go-up   go-down


95. Ogawa H, Itoh S, Ikeda M, Suzuki K, Naganawa S: Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT. Radiology; 2008 Sep;248(3):876-86
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT.
  • PURPOSE: To evaluate the capabilities of multisection computed tomography (CT) in determining the likelihood of invasiveness of intraductal papillary mucinous neoplasm (IPMN).
  • Two radiologists blinded to the pathologic assessment of malignancy or parenchymal invasion of IPMN retrospectively evaluated CT images of 61 consecutive surgically resected tumors (26 adenomas, 15 noninvasive carcinomas, and 20 invasive carcinomas) in patients who underwent multiphase contrast material-enhanced CT with 0.5- or 1-mm collimation.
  • CONCLUSION: Multisection CT is useful for distinguishing among adenoma, noninvasive carcinoma, and invasive carcinoma in patients with IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Adenoma / radiography. Pancreatic Neoplasms / radiography. Papilloma, Intraductal / radiography. Radiographic Image Enhancement / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2008
  • (PMID = 18632526.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Sofiadis A, Dinets A, Orre LM, Branca RM, Juhlin CC, Foukakis T, Wallin G, Höög A, Hulchiy M, Zedenius J, Larsson C, Lehtiö J: Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca2+ -binding protein S100A6 in papillary thyroid carcinoma. Thyroid; 2010 Oct;20(10):1067-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca2+ -binding protein S100A6 in papillary thyroid carcinoma.
  • METHODS: Protein fractions from 29 frozen thyroid tumor tissue samples (10 papillary carcinomas, 9 follicular carcinomas, and 10 follicular adenomas) as well as from normal thyroid tissue were analyzed by surface enhanced laser desorption/ionization time-of-flight mass spectrometry followed by validation by Western blotting and immunohistochemistry.
  • RESULTS: A Ca2+ binding protein belonging to the S100 family, S100A6, was differentially expressed between papillary and follicular thyroid tumors.
  • Validation by Western blotting displayed a significantly higher expression of S100A6 in papillary thyroid carcinoma (PTC) in comparison with the other tumor groups or normal tissue (p < 0.05).
  • [MeSH-major] Carcinoma, Papillary / genetics. Cell Cycle Proteins / genetics. S100 Proteins / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thyroid. 2010 Oct;20(10):1051-2 [20883170.001]
  • (PMID = 20629554.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / S100 Proteins; 105504-00-5 / S100A6 protein, human
  •  go-up   go-down


97. Bussom S, Saif MW: Intraductal papillary mucinous neoplasia (IPMN). Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP; 2010;11(2):131-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasia (IPMN). Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
  • The diagnosis and treatment of intraductal papillary mucinous tumors (IPMN) of the pancreas has evolved over the last decade.
  • IPMN is a disease of the ductal epithelium and represent a spectrum of disease, ranging from benign to malignant lesions, making the early detection and characterization of these lesions important.
  • As with villous adenomas of the colon, not all IPMNs will develop into adenocarcinoma.
  • Definitive management is surgical resection for appropriate candidates, as benign lesions harbor malignant potential.
  • [MeSH-minor] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Carcinoma, Papillary / classification. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Congresses as Topic. Cyst Fluid / chemistry. Cytokines / analysis. Early Detection of Cancer / methods. Enzyme-Linked Immunosorbent Assay. Gastrointestinal Neoplasms / diagnosis. Humans. Models, Biological. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20208320.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 26
  •  go-up   go-down


98. Keramidas EG, Miller G, Revelos K, Kitsanta P, Page RE: Aggressive digital papillary adenoma-adenocarcinoma. Scand J Plast Reconstr Surg Hand Surg; 2006;40(3):189-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive digital papillary adenoma-adenocarcinoma.
  • Aggressive digital papillary adenocarcinoma and aggressive digital papillary adenoma are rare tumours of the sweat glands.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687341.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Yasuda M, Ogane N, Hayashi H, Kameda Y, Miyagi Y, Iida T, Mori Y, Tsukinoki K, Minematsu T, Osamura Y: Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol Rep; 2005 Dec;14(6):1499-504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma.
  • Glucose transporter-1 (GLUT-1) expression was immunohistochemically analysed in a total of 268 cases of thyroid gland disease, including 129 cases of papillary carcinoma (PC), 60 cases of follicular carcinoma (FC), 57 cases of follicular adenoma, and 22 cases of adenomatous goitre.
  • GLUT-1 expression was observed in 5% (3/60) of FC cases, but all follicular adenomas and adenomatous goitres were negative for GLUT-1 (PC vs. FC, p<0.0001).
  • Semi-quantitative analysis of glut-1 mRNA by RT-PCR showed a tendency toward higher expression in PCs compared to FCs, follicular adenomas and adenomatous goitres, and the mRNA expression in PCs with a membrane-like pattern was higher than those showing cytoplasm-predominance.
  • 1) GLUT-1 is immunohistochemically useful in distinguishing PC from FC and benign diseases;.
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / metabolism. Adenoma / pathology. Blotting, Western. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Papillary / secondary. Gene Expression. Humans. Immunohistochemistry. Lymphatic Metastasis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273245.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / RNA, Messenger
  •  go-up   go-down


100. Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA: Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol; 2010 Sep;23(9):1191-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
  • The follicular variant of papillary thyroid carcinoma usually presents as an encapsulated tumor and less commonly as a partially/non-encapsulated infiltrative neoplasm.
  • The molecular profile of the follicular variant was shown to be close to the follicular adenoma/carcinoma group of tumors with a high RAS and very low BRAF mutation rates.
  • A comprehensive survey of oncogenic mutations in the follicular variant of papillary thyroid carcinoma according to its encapsulated and infiltrative forms has not been performed.
  • Encapsulated follicular variant of papillary thyroid carcinomas have a molecular profile very close to follicular adenomas/carcinomas (high rate of RAS and absence of BRAF mutations).
  • Infiltrative follicular variant has an opposite molecular profile closer to classical papillary thyroid carcinoma than to follicular adenoma/carcinoma (BRAF>RAS mutations).
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Genes, ras / genetics. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526288.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA050706; United States / NCI NIH HHS / CA / R01 CA072597
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Other-IDs] NLM/ NIHMS720090; NLM/ PMC4573468
  •  go-up   go-down






Advertisement